| 3244 | Vojtech Huser | National Library of Medicine/NIH | Identification of Research Common Data Elements in HIV/AIDS | AbbVie, Pfizer Inc. |
| 3246 | Dawn Farrell | Institute of Technology Tralee | Cochrane Review: Interventions for fatigue in inflammatory bowel disease | AbbVie |
| 3270 | Mirjana Stanic Benic | UHC Rijeka | The impact of biological interventions on health‐related quality of life in adults with Crohn's disease | AbbVie, Biogen |
| 3287 | Robert Alexander | Takeda | Identification of biomarkers associated with specific sleep variables | GlaxoSmithKline |
| 3288 | Marc-Antoine Sparfel | Tours Hospital | MIDRA : influence of demographic and environmental factors on anti- tumor necrosis factor efficacy in rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials | AbbVie, Pfizer Inc., UCB |
| 3320 | John Frew | Rockefeller University | Analysis of Outcome Measures in Hidradenitis Suppurativa | AbbVie |
| 3321 | Ewa Olech | IQVIA | Optimization of lupus trial design based on entry variables | GlaxoSmithKline |
| 3328 | Klaus Gottlieb | Eli Lilly USA | Mapping of components of the complete blood count and comprehensive metabolic profile to disease-specific clinical and endoscopy endpoints in phase 2 and 3 clinical trials of ulcerative colitis and Crohn’s disease | Takeda |
| 3361 | Gustav Nilsonne | Karolinska Institutet | Interleukin-6 distribution in plasma/serum | GlaxoSmithKline, AbbVie |
| 3369 | Michael Ward | NIH | Predicting Treatment Response to Tumor Necrosis Factor Inhibitors in patients with ankylosing spondylitis | AbbVie, Pfizer Inc. |
| 3762 | Lin Wang | Johns Hopkins School of Public Health, Johns Hopkins Hospital | The relative efficacy and safety of apalutamide, enzalutamide, abiraterone, and darolutamide for nonmetastatic castration-resistant prostate cancer | Project Data Sphere, LLC, Pfizer Inc. |
| 3876 | Changyu Shen | Beth Israel Deaconess Medical Center, | Risk and Benefit Stratification of Treatment Effects in Patients with Atrial Fibrillation | Daiichi Sankyo, Inc., Boehringer Ingelheim |
| 4036 | Akira Kimata | Department of Cardiology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan | Dabigatran Integrated Analysis | Boehringer Ingelheim |
| 4037 | Karl Peace | Jiann-Ping Hsu College of Public Health, Georgia Southern University | Assessment of Matching Methods for Causal Analysis | Boehringer Ingelheim |
| 4039 | claire daien | CHU lapeyronie | Non-MTX-csDMARDs versus MTX in combination with tofacitinib: a post hoc analysis | Pfizer Inc. |
| 4041 | Vivek Rudrapatna | University of California, San Francisco | Enhancing inference from real-world data using externally-derived missing data models: a pilot study of Ulcerative Colitis | Takeda, AbbVie, Johnson & Johnson |
| 4043 | Janneke van der Woude | Dept. of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands | Tofacitinib ulcerative colitis | Pfizer Inc. |
| 4047 | Miriam Oron | Skintelligence ltd. | biological drugs data analysis | ImmPort (a data-sharing platform funded by the National Institutes of Health) |
| 4113 | Lesley Inker | Division of Neprology, Tufts Medical Center | Chronic Kidney Disease Epidemiology – Clinical Trials Consortium (CKD-EPI CT) | GlaxoSmithKline, Takeda |
| 4115 | Amir Mahabadi | University Hospital Essen, West German Heart and Vascular Center, Department of Cardiology and Vascular Medicine | Impact of statin therapy on coronary artery calcification volume and density – A meta-analysis of randomized controlled trials | Pfizer Inc. |
| 4116 | Sharon Strauss | St. Michael’s Hospital | Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: a systematic review and individual patient data network meta-analysis | AbbVie |
| 4117 | John Frew | Rockefeller University | Predictors of Treatment Response, Adverse Events, Changes in Anaemia status and Assessment of Lesion Count Variability in Hidradenitis Suppurativa | AbbVie |
| 4118 | J. David Spence | Western University, London, ON, Canada | On-Treatment analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial | Pfizer Inc. |
| 4120 | Merryn Voysey | Oxford Vaccine Group, University of Oxford | The immunogenicity and sero-efficacy of pneumococcal vaccines | Pfizer Inc. |
| 4121 | Frederikus Klok | Leiden University Medical Center | Performance of the AF-adapted VTE-BLEED score for predicting major bleeding in patients with atrial fibrillation: a post-hoc analysis of the ENGAGE-AF TIMI-48 Study | Daiichi Sankyo, Inc. |
| 4275 | Lisa Stamp | University of Otago, Christchurch | Serum urate as a biomarker in gout: Protocol for individual patient data analysis for OMERACT 2020 | Takeda |
| 4278 | Jennifer Quint | Imperial College London | Withdrawing inhaled corticosteroid (ICS) treatment in people with COPD: a real world study | Boehringer Ingelheim |
| 4316 | Martin Okun | Fort HealthCare | Geospatial and Seasonal Variation in Psoriasis Severity: Analysis of Placebo Response Data from Phase 3 placebo-controlled trials in moderate-severe psoriasis | AbbVie |
| 4319 | Maria Alice Franzoi | Jules Bordet Institut | Clinical implications of body mass index and weight in metastatic breast cancer patients receiving abemaciclib. A combined individual patient level data sub-analysis of MONARCH 2 and MONARCH 3 trials. | Lilly |
| 4324 | Peng Xie | Institute of Neuroscience, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District Chongqing, china | Comparative efficacy and tolerability of new-generation antidepressants for major depressive disorder in children and adolescents: an individual patient data meta-analysis | Lilly, GlaxoSmithKline, Pfizer Inc. |
| 4326 | John Markman | University of Rochester | Phenotypic Characterization of Chronic Neuropathic Pain Following Post-Traumatic and Post-Surgical Injury | Pfizer Inc. |
| 4327 | Michael Szarek | SUNY Downstate Medical Center | Analysis of Total Events and Hospitalizations in the SPARCL Study | Pfizer Inc. |
| 4329, 4048 | Shomron Ben-Horin | Sheba Medical Center, Tel- Aviv University, Israel & Sun Yatsen 1st affiliated Hospital, Guangzhou China | Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient level meta-analysis of randomized controlled trials - revised | Takeda, Biogen, AbbVie, UCB, Johnson & Johnson |
| 4330 | Laure Gossec | Sorbonne Université, Paris, France | Domains of health important for Rheumatoid Arthritis patients can be assessed separately: Reliability and Responsiveness of the Rheumatoid Arthritis Impact of Disease Score - 7 items (RAID.7i) | Pfizer Inc. |
| 4352 | Stefano Barco | University Medical Center Mainz; Clinic for Angiology Zürich | Differential effects of long-term treatment with warfarin vs. edoxaban on blood count parameters. A parallel posthoc analysis of the Hokusai VTE and Engage AF-TIMI-48 trials | Daiichi Sankyo, Inc. |
| 4540 | Chris Gale | University of Leeds | Efficacy and safety of edoxaban versus warfarin in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial | Daiichi Sankyo, Inc. |
| 4541 | C Elizabeth Caldon | Garvan Institute of Medical Research | Therapeutic targeting of dual CDK4/6 inhibitor and endocrine resistant breast cancer | Pfizer Inc. |
| 4913 | Susan Halabi | Duke University | Surrogate Endpoints of Overall Survival in Non-Metastatic Renal Clear Cell Carcinoma | Project Data Sphere, LLC, Pfizer Inc. |
| 4915 | Rachel Tomko | Medical University of South Carolina | Predicting Individuals' Probability of Response to Smoking Cessation Pharmacotherapy | Pfizer Inc. |
| 4917 | Andrea Cipriani | University of Oxford | Choosing the Right Antidepressant for Depressive Disorder in Adults: Individual Patient Data Network Meta-Analysis | Lilly, GlaxoSmithKline, Lundbeck |
| 4918 | Nina Hilkens | Radboudumc Nijmegen | Blood pressure variability and cognitive decline | Boehringer Ingelheim |
| 4919 | Hendrik Jan Guchelaar | Leiden University Medical Center (LUMC) | Effect of digoxin on survival outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors | Pfizer Inc. |
| 4920 | Gustavo Turecki | Douglas Mental Health University Institute | Predicting Treatment Efficacy in Individuals with Major Depression -- Deep Neural Networks for Physiological Patient Parameters | Pfizer Inc. |
| 4921 | Tim Brümmendorf | University Hospital Aachen | Entropy – based Biomarkers for individualized response on Bosutinib treatment in chronic phase CML - Brummendorf | Pfizer Inc. |
| 4922, 3274 | Diane van der Woude | Leiden University Medical Center | Effect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis | Pfizer Inc., AbbVie |
| 4926 | Eva-Maria Gamper | Medical University Innsbruck | Comparison of the EORTC QLU-C10D (a cancer-specific utility instrument) with generic utility instruments and development of a comprehensive manual for its use | Boehringer Ingelheim |
| 4931 | Siddharth Singh | University of California San Diego | Early changes in inflammatory biomarkers and long-term outcomes in patients with IBD: A pooled post-hoc analyses of clinical trials | AbbVie, Takeda |
| 4933 | Hongxia Wang | Department of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | PALOMA-2 Data Request for Biomarker Analysis | Pfizer Inc. |
| 4949, 3190 | Vivek Rudrapatna | University of California San Francisco | Efficacy of Crohn's Disease Treatment Stratified by Disease Phenotype | AbbVie, Takeda, Johnson & Johnson, Biogen, UCB |
| 4950 | John "Devin" Peipert | Northwestern University | Justification of PROMIS (FACIT) Fatigue Short Form 10a scale for FDA Drug Development Tool Qualification in Rheumatoid Arthritis | AbbVie |
| 5073 | Philip Robinson | University of Queensland | Assessment of treatment outcome with etanercept in nraxSpA
by baseline CRP | Pfizer Inc. |
| 5074 | Sebastian Zundler | University Hospital Erlangen, Department of Medicine 1 | Evaluation of the relationship between vedolizumab peripheral blood serum level at week 6 and binary clinical outcomes at week 10/14 in ulcerative colitis and Crohn's disease - meta-analysis | Takeda |
| 5079 | Maureen Dubreuil | Boston University School of Medicine | Clinical and MRI predictors of Clinical Response in Axial Spondyloarthritis | AbbVie |
| 5080 | Joel Skaistis | Beaumont Health | ABC-EBUS | Boehringer Ingelheim |
| 5086 | Junko Takeshita | University of Pennsylvania | A Systematic Review to Describe the Demographic Diversity of Dermatologic Clinical Trial Participants for Common Dermatologic Diseases | Lilly, AbbVie, Regeneron |
| 5095 | Mathilde Nijkeuter | University Medical Center Utrecht | Assessing bleeding risk in patients with cancer-associated thrombosis | Daiichi Sankyo, Inc. |
| 5096 | Joo Sang Lee | Samsung Medical Center, South Korea | Harnessing genetic interactions to advance precision cancer medicine | Tempus AI, Inc. |
| 5098 | Christopher Baethge | Department of Psychiatry University of Cologne Medical School | (S)SNRI dose response realtionship | Lilly |
| 5099 | Jorge Hernando | Vall d´Hebron University Hospital | Impact of gender on multikinase inhibitors (MKIs) toxicity in patients (pts) with advanced pancreatic and gastrointestinal neuroendocrine tumors | Pfizer Inc. |
| 5163 | Susan Bates, MD | Columbia University Medical Center | Assessing the tumor growth and decay rates in patients with pancreatic cancer treated with Gemcitabine/Abraxane: Comparing real world data with clinical trial data | Celgene Corporation |
| 5165 | Byeongzu Ghang | Division of Rheumatology, Jeju National University School of Medicine, Jeju National University Hospital, Jeju, Republic of Korea | Reanalysis of CARES study to investigate the incidence of cardiovascular events and death after initiation and discontinuation of allopurinol and febuxostat | Takeda |
| 5166 | Thomas Metkus | Johns Hopkins University School of Medicine | Severe sepsis in the cardiac intensive care unit: management strategies and outcomes | Lilly |
| 5207 | Fasihul Khan | University of Nottingham, UK | A systematic review and individual patient data meta-analysis of physiological biomarkers in idiopathic pulmonary fibrosis | Boehringer Ingelheim, Johnson & Johnson, BioLINCC (a data-sharing platform funded by the National Institutes of Health), Roche |
| 5209 | Bruce Perkins | Sinai Health System, University of Toronto | TRIAL-INFORMED DKA MITIGATION EDUCATIONAL TOOL: THE TORONTO-MICHIGAN PATIENT-PROVIDER COLLABORATIVE | Boehringer Ingelheim |
| 5276 | Yan Luo | Kyoto University | Predicting the Treatment Response of Certolizumab for Individual Patients with Rheumatoid Arthritis: An Individual Participant Data Meta-Analysis - Luo | UCB |
| 5290 | Ashley Hopkins | Flinders University | Predictors of therapeutic and adverse effects of medicines used in the treatment of GI cancers. | Lilly, Roche, Boehringer Ingelheim, GlaxoSmithKline |
| 5291 | Sarah Nevitt | Department of Biostatistics, University of Liverpool, United Kingdom | Antiepileptic drug monotherapy for epilepsy: an updated Cochrane review and individual participant data network meta-analysis | UCB |
| 5292 | Désirée van der Heijde | Leiden University Medical Center | Measurement properties of the instruments used in the outcome assessment of axial spondyloarthritis | UCB |
| 5294 | Daniel Caldeira | CCUL - Faculdade de Medicina da Universidade de Lisboa | The clinical impact of dabigratran in patients with non-valvular atrial fibrillation who had a fall or head injury: a retrospective analysis of RE-LY | Boehringer Ingelheim |
| 5325, 5324 | Daniel Goldenholz | Beth Israel Deaconess Medical Center, Harvard Medical School | Retrospective analysis of placebo arm data in clinical epilepsy trials -Goldenholz | UCB, GlaxoSmithKline |
| 5330 | Laura Bonnett | University of Liverpool | Modelling seizure rates within clinical trials of antiepileptic drugs - Bonnett | UCB |
| 5352 | Elena Myasoedova | Mayo Clinic | Individualized Prediction of Treatment Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach - Myasoedova | UCB, Roche |
| 5435 | Matthew Gilbert | Larner College of Medicine at The University of Vermont | Effect of Albiglutide on Cardiovascular Outcomes in Older Adults | GlaxoSmithKline |
| 5436 | Adrian Wagg | University of Alberta | A pooled analysis of the efficacy and tolerability of tolterodine for the treatment of Overactive Bladder (OAB) in patients over the age of 65 years of age
| Pfizer Inc. |
| 5456 | Ramona Belfiore-Oshan | Critical Path Institute | Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy | Cure Duchenne |
| 5483 | David McAllister | University of Glasgow | Heterogeneity in relative treatment efficacy by age, sex, socioeconomic status and comorbidity (McAllister) | Boehringer Ingelheim, Takeda, UCB, Lilly, Roche |
| 5567 | Neeraj Narula | McMaster University | Endoscopic Healing Predictors | AbbVie |
| 5812 | Yougen Wu | The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China | Development and validation of nomograms for predicting efficacy and toxicity in cancer patients treated with immune checkpoint inhibitors | Roche |
| 5813 | Phillip Garfin | Seattle Genetics Inc | Effectiveness of cytotoxic chemotherapy for the treatment metastatic breast cancer subtypes (Garfin 11387) | Roche |
| 5852 | Marliese Alexander | Peter MacCallum Cancer Centre | Infective outcomes in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: an individual patient data meta-analysis | Roche |
| 5853 | Florian Naudet | Univ Rennes, CHU Rennes, Inserm, CIC 1414 [(Centre d’Investigation Clinique de Rennes)], F- 35000 Rennes, France | Data-sharing and re-analysis for main studies assessed by the European Medicines Agency - a
cross-sectional study on European Public Assessment Reports
| AbbVie |
| 5869 | Alexandra Freeman | University of Cambridge | Meta-analysis of the adverse effects of trastuzumab in women with breast cancer | Roche |
| 5871 | Nobuhisa Kanahara | Chiba University Center for Forensic Mental Health | Determination of dopamine supersensitivity psychosis in randomized controlled studies of long-acting injectable vs. oral agents of the same atypical antipsychotic in schizophrenia subjects | Lilly |
| 5872 | Yaw Nyame | University of Washington Medical Center | Representation of Low-Grade Prostate Cancer in Metastatic Prostate Cancer Trials | Pfizer Inc. |
| 5880 | Benjamin Schneider | Iowa State University | Optimal Scheduling of First-Line Therapeutics in Non-Small Cell Lung Cancer | Lilly, Roche |
| 5894 | Takashi Sozu | Tokyo University of Science | Matrix Decomposition in Meta-Analysis for Extraction of Adverse Event Pattern and Patient-Level Safety Profile | Lilly |
| 5897 | John Peipert | Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine | FACIT Fatigue in Rheumatoid Arthritis in Pfizer Trials | Pfizer Inc. |
| 5901 | Junhao Hu | Interdiscipline Research Center on Biology and Chemistry, Chinese Academy of Science | sGC change in COVID-19 patients lung | Hannover Medical School |
| 5902 | Thrasyvoulos Tzellos | Department of Dermatology, Nordland University Hospital, Bodø, Norway | Development and validation of a IHS4 dichotomous outcome for assessing anti-inflammatory treatment efficacy for the treatment of hidradenitis suppurativa | AbbVie |
| 5904 | Saskia Middeldorp | Amsterdam UMC, location AMC, University of Amsterdam | Hokusai post VTE study: long-term outcome after heparin plus edoxaban versus heparin plus vitamin K antagonists for acute deep vein thrombosis and pulmonary embolism | Daiichi Sankyo, Inc. |
| 5921 | Paul Schulz | University of Texas Health Science Center Houston | Identification of biomarkers associated with Alzheimer’s disease progression that correlate with responses to medications. | Lilly |
| 5924 | Iris Sommer | UMCG | Meta-analysis of efficacy of cholinesterase inhibitors on individual neuropsychiatric symptoms in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies | GlaxoSmithKline, AbbVie, Johnson & Johnson |
| 5925 | Min Hwan Kim | Division of Medical Oncology, Yonsei University College of Medicine | CDK4/6 inhibitor NLR | Pfizer Inc. |
| 5930 | Youssef Zeidan | American University of Beirut Medical Center | Evaluation of Radiotherapy Boost in Women with HER-2 positive Breast Cancer | Roche |
| 5931 | Youssef Zeidan | American University of Beirut Medical Center | Evaluation of Radiation Therapy in Triple Negative Breast Cancer | Roche |
| 5933, 5208 | Ahmad Abuhelwa | University of South Australia | Predictors of exposure, therapeutic and adverse effects of certolizumab pegol, baricitinib and tocilizumab used in the treatment of rheumatoid arthritis. | UCB, Lilly, Roche |
| 5940 | Aziz Mezlini | Massachusetts General hospital/ Harvard Medical school | A novel statistical approach to detect the efficacy of drugs that have heterogeneous treatment effects | GlaxoSmithKline, Takeda, AbbVie, Lundbeck, Boehringer Ingelheim, Roche, Johnson & Johnson, UCB |
| 5944 | Pietro Spitali | Leiden University Medical Center | Prediction of disease progression in Duchenne muscular dystrophy | Cure Duchenne |
| 5945 | Neeraj Narula | McMaster University | Predictors of Mucosal Healing in Ulcerative Colitis: A Post-hoc Analysis of VARSITY | Takeda |
| 5948 | Georgia Salanti | Institute of Social and Preventive Medicine. University of Bern, Switzerland | HTx project | Biogen |
| 5950 | Shirley Wang | Brigham and Women's Hospital | Understanding effectiveness of new drugs in older adults shortly after market entry | Boehringer Ingelheim |
| 5951, 4543 | Mathilde Nijkeuter | UMC Utrecht | INDIVIDUALIZED PREDICTION OF RECURRENCE RISK REDUCTION AND RISK OF BLEEDING WITH EXTENDED ANTICOAGULATION IN PATIENTS WITH VENOUS THROMBOEMBOLISM v2.0 | Daiichi Sankyo, Inc., Boehringer Ingelheim |
| 5959 | John Dennis | University of Exeter Medical School | Stratification of SGLT2 inhibitor glucose lowering therapy in Type 2 diabetes | Boehringer Ingelheim, Takeda |
| 5960 | Matt Linnik | Eli Llilly | Covid-19 Pulmonary Gene Expression Analysis | Hannover Medical School |
| 5963 | Elyse Katz | Department of Defense, USSAMMDA | A secondary Data-Analysis to determine treatment effectiveness in Post-Traumatic Stress Disorder | Lilly |
| 5968 | Mehul Patel | King's College Hospital NHS Foundation Trust | Methods for Staging disease activity In ulcerative colitis; A comparison of endoscopy and Histology (MESIAH) | Takeda, Johnson & Johnson |
| 5974 | Robert Schoevers | University Medical Center Groningen, department of psychiatry, University of Groningen (RUG) | Prescriber effects on outcome of psychopharmacological treatment of Major Depressive Disorder (MDD) | Lilly |
| 5981 | Mark Peterson | Vertex Pharmaceuticals, Inc. | Identifying and quantifying predictors of disease progression in common measures of physical function among boys with Duchenne Muscular Dystrophy (DMD) | Cure Duchenne, Lilly |
| 5982 | Matthew Baker | Stanford University | Investigating the effects of rituximab on specific cell subsets and cytokine levels in systemic lupus erythematosus patients and constructing a prediction model of treatment response | Roche |
| 5984 | David Baker | Queen Mary University of London | Exploring possibilities to improve the risk: benefit balance through analysis of the ocrelizumab phase II extension study | Roche |
| 5985, 5327 | Jose Antonio Pereira da Silva | Universidade de Coimbra, Portugal | Long-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysis | AbbVie, UCB, Pfizer Inc., Roche |
| 5988 | Elad Sharon | National Cancer Institute | The Role of Targeted Agents and Their Effects on Lymphocytes and Patient Outcomes | Roche |
| 5989 | Alexandre Betourne | Critical Path Institute | Sharing of Progressive Supranuclear Palsy (PSP) data with the Rare Disease Cures Accelerator- Data and Analytics Platform for Analysis of Outcome Measures and Other Purposes | AbbVie |
| 5990 | Yan Luo | Kyoto University | Predicting the Treatment Response of Biologics for Individual Patients with Rheumatoid Arthritis: An Individual Participant Data Meta-Analysis | AbbVie, Roche |
| 6003 | Andrea Quattrone | Magna Graecia University of Catanzaro, Italy | Evaluation of disease progression rate in progressive supranuclear palsy using MRI biomarkers: new implications for clinical trials | AbbVie |
| 6004 | Lily Lim | Rady Faculty of Health Sciences, University of Manitoba | Identifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change Treatment | Roche |
| 6006 | Nicholas White | Mahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University | A Multiple-Dose Study to Assess the Effects of Azithromycin plus Chloroquine on Electrocardiograms in Healthy Subjects - COVID-19 | Pfizer Inc. |
| 6007 | Judith Goldstein | Johns Hopkins School of Medicine | National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) Calibrations for Low Vision Patients with age-related macular degeneration (AMD) | Roche |
| 6008 | David Hsieh | University of Texas Southwestern Medical Center | Patterns of outcomes and the relevance surrogate endpoints in patients treated with immune checkpoint inhibitors | Roche |
| 6041 | Neeraj Narula | Hamilton Health Sciences | Histologic Predictors of Endoscopic Healing in Crohn's Disease | AbbVie |
| 6050 | Paul Cinciripini | UT MD Anderson Cancer Center | Safety and efficacy of smoking cessation treatments in smokers with and without depression | Pfizer Inc. |
| 6055, 7744 | Florian Naudet | CHU Rennes | Inferential reproducibility of therapeutic research: a registered report for a cross-sectional study of RCTs available on major data-sharing platforms | BioLINCC (a data-sharing platform funded by the National Institutes of Health), Boehringer Ingelheim, ImmPort (a data-sharing platform funded by the National Institutes of Health), Pfizer Inc., Takeda, AbbVie, Roche, UCB, Lilly, Project Data Sphere |
| 6062 | Alexander Meisel | University Hospital of Zurich | Neutrophils, NLR and Neutropenia as Predictors of Treatment Efficacy of Atezolizumab Monotherapy and Atezolizumab-Chemotherapy-Combinations | Roche |
| 6063 | Wiesje van der Flier | Amsterdam UMC, VUmc | Optimizing Trial design to Achieve Personalized prevention of Alzheimer’s disease | GlaxoSmithKline, Lilly, Boehringer Ingelheim, Johnson & Johnson |
| 6064 | Neeraj Narula | Hamilton Health Sciences | Comparative Effectiveness of Vedolizumab vs. Infliximab in Ulcerative Colitis | Takeda, Johnson & Johnson |
| 6066 | Vivek Sharma | University of Louisville | EVALUATING THE ASSOCIATION BETWEEN PROTEINURIA AND THROMBOSIS AND ITS PREDICTORS IN PATIENTS TREATED WITH BEVACIZUMAB | Roche, Lilly, Boehringer Ingelheim |
| 6104 | Pratik Sinha | Department of Anesthesia, Washington University | Heterogeneous treatment effects in molecular phenotypes of sepsis | Lilly |
| 6464 | Michael Wiese | University of South Australia | Individualisation of gout flare prophylaxis when initiating urate-lowering therapy | Takeda |
| 6471 | Vincent Lanting | University of Amsterdam Academic Medical Center | Risk of recurrent venous thromboembolism and bleeding in cancer patients: an individual patient data meta-analysis | Pfizer Inc. |
| 6472 | Soong June Bae | Gangnam Severance Hospital, Yonsei University College of Medicine | Impact of neutrophil to lymphocyte ratio and BMI on prognosis in patients with HER2-positive breast cancer regarding the HER2-targeted therapy | Roche |
| 6475 | Tobias Polak | Erasmus Medical Center, Erasmus University Rotterdam | Combining data from expanded access programs and conventional clinical trials: a statistical application to vemurafenib | Roche |
| 6477 | Tobias Polak | Erasmus Medical Center, department of Biostatistics | Tositumomab : statistical modeling of expanded access programs and conventional trials | GlaxoSmithKline |
| 6482 | Andreas Monsch | University Department of Geriatric Medicine FELIX PLATTER, University of Basel, Switzerland | Analyses of available cognitive data from 200 healthy, German-speaking individuals to be used to examine potential patients | Takeda |
| 6483 | Bharati Kumar | University of Bath | Evaluation of available statistical methods performance under non-proportional hazards | Lilly, AstraZeneca |
| 6484 | Ari Rosenberg | University of Chicago | Developing predictive and prognostic Artificial Intelligent (AI) digital biomarkers for soft tissue sarcoma | Lilly |
| 6489 | Line Uhrenholt | Aalborg University Hospital | Tapering strategies of biological and targeted synthetic disease-modifying antirheumatic drugs for patients with inflammatory arthri-tis: a systematic review of randomised controlled trials
| AbbVie |
| 6494 | Maria Alice Franzoi | Institut Jules Bordet | Implications of body mass index on the biological and clinical effects of endocrine therapy and abemaciclib in the neoadjuvant setting | Lilly |
| 6495, 5485 | Günter Höglinger | Department of Neurology, Hanover Medical School, Hanover, Germany | Application of improved statistical methodologies for clinical trials in Progressive Supranuclear Palsy | AbbVie |
| 6496 | Neeraj Narula | Hamilton Health Sciences | Endoscopic Disease Severity and Patient Reported Outcomes in Crohn’s Disease | Johnson & Johnson, AbbVie |
| 6498 | Timo Uphaus | University Medical Center Mainz | Identifying patients with unknown stroke etiology who may benefit from a blood thining medication with Dabigatran by a clinically based scoring system | Boehringer Ingelheim |
| 6499, 5323, 5289 | Ashley Hopkins | Flinders University | Predictors of therapeutic and adverse effects of medicines used in the treatment of breast cancer_012021 | Lilly, Roche, Boehringer Ingelheim, Pfizer Inc., AstraZeneca |
| 6515 | Leire Leache | Navarre Health Service (Spain) | Cochrane systematic review-Pharmacotherapy for hypertension-induced left ventricular hypertrophy | Boehringer Ingelheim |
| 6521 | Ethan Alt | University of North Carolina at Chapel Hill | Bayesian probability of success for multivariate generalized linear models | Biogen |
| 6532 | Odelia Cooper | Cedars-Sinai Medical Center | A study of how growth hormone treatment affects health outcomes inpatients with noncancerous craniopharyngioma tumors | Lilly |
| 6534 | Diego Tosi | Institut du Cancer de Montpellier (ICM), Montpellier, France | Analysis of breast cancer molecular adaptation to drugs in order to predict relapse after curative treatment | Lilly |
| 6541 | Dipak Kotecha | University of Birmingham, Institute of cardiovascular sciences | Big data and meta-analytic approaches for better phenotyping in atrial fibrillation and heart failure | Boehringer Ingelheim |
| 6543 | Andreas Meid | Heidelberg University Hospital | Reproducible Machine Learning (ML) for Tumor Growth Inhibition (TGI) - can ML methods support the validity of conventional TGI metrics? | Roche |
| 6544 | Angela Wu | Oxford University | Investigating the association between smoking cessation and mental health in people with and without psychiatric disorders | Pfizer Inc. |
| 6550 | James Brorson | The University of Chicago | Examination of survivor functions from SOCRATES and THALES trials for kinetics of stroke recurrence | AstraZeneca |
| 6551 | Siddharth Singh | University of California San Diego | Predicting the short- and long-term risk of serious infections in patients with Crohn’s disease: Analysis of the PYRAMID Registry | AbbVie |
| 6593 | Matthieu Roustit | Centre d'Investigation Clinique, Inserm CIC1406 CHU Grenoble AlpesLaboratoire HP2, Inserm UMR 1042 | Exploration of regional heterogeneity in trials assessing the efficacy of recent non-insulin glucose lowering drugs on cardiovascular outcomes | AstraZeneca |
| 6594 | Manju Subramanian | Boston University Medical Center | The Impact of Race on Short Term Treatment Response to Intravitreal anti-Vascular Endothelial Growth Factor in Diabetic Macular Edema: A Pooled Analysis | Roche |
| 6601 | Dan Turner | Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Israel | Adaptation and validation of the Mucosal Inflammation Non-invasive (MINI) Index for Crohn's disease in adults using the SERENE clinical trial data | AbbVie |
| 6632 | Luca Valerio | Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University Mainz | Healthcare resource utilization and economic burden related to pulmonary embolism. An analysis of the PREFER in VTE study. | Daiichi Sankyo, Inc. |
| 6633 | Luca Valerio | Center of Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany; Department of Cardiology | Performance status and long-term clinical outcomes in pulmonary embolism patients with cancer. An analysis of Hokusai VTE Cancer study | Daiichi Sankyo, Inc. |
| 6641 | Anna Feeney | Massachusetts General Hospital/ Harvard Medical School | Antidepressants in children and adolescents with Major Depressive Disorder and the influence of placebo response: a meta-analysis | Pfizer Inc. |
| 6642 | Neeraj Narula | Hamilton Health Sciences | Modified Multiplier SES-CD (MM-SES-CD) on Predicting Endoscopic Remission in Crohn’s Disease | AbbVie, Takeda, Johnson & Johnson |
| 6686 | Neeraj Narula | Hamilton Health Sciences | Extended Validation of an Ulcerative Colitis Vedolizumab Decision Support Tool | Takeda |
| 6710 | Gus Slotman | Inspira Health Network, Vineland, NJ | Identifying Patients in the PROWESS SHOCK Clinical Trial Among Whom Drotrecogin Alfa (DrottAA) Reduced Mortality | Lilly |
| 6712 | Yeon-Mok Oh | Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea | Development and validation of a prediction model for the indication of inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD) | GlaxoSmithKline |
| 6716 | Nigam Shah | Stanford Universty | Applying machine learning tools to personalize dabigatran treatment decisions | Boehringer Ingelheim |
| 6732 | Yung-Chuan Huang | Fu Jen Catholic University | Decision Tree Model for Dose Selection in Non-valvular Atrial Fibrillation Patients | Boehringer Ingelheim |
| 6734 | Andreas Suhrbier | QIMR Berghofer Medical Research institute | The K18 mouse model recapitulates the transcriptomic response to acute COVID-19 Acute Respiratory Distress syndrome (ARDS) in humans | Hannover Medical School |
| 6739 | Rifaquat Rahman | Dana-Farber/Brigham and Women's Cancer Center (Dana-Farber Cancer Institute) | Evaluation of Differences in Trial and Non-Trial Patients and Leveraging of External Data for More Efficient Clinical Trial Designs in Newly Diagnosed Glioblastoma | Roche, Project Data Sphere |
| 6740 | Georgios Paliouras | National Center for Scientific Research "Demokritos", Greece | in-silico DMD: Developing computational predictive models for the progression of Duchenne Muscular Dystrophy | Cure Duchenne |
| 6758 | Qian Chen | Hubei Cancer Hospital | Retrospective analysis of the effect of first-line bevacizumab treatment on survival and prognosis of patients with advanced non-small cell lung cancer treated with second-line immunotherapy | Roche |
| 6759, 5936 | Zhi Xiao | Xiangya Hospital, Central-South University | Roles of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy | Roche |
| 6762, 5935 | Jian-Guo Zhou | Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Project Data Sphere, Roche, Bristol Myers Squibb |
| 6764 | Jonathan Bartlett | London School of Hygiene and Tropical Medicine | Hypothetical estimands in clinical trials: an application of causal inference and missing data methods | AstraZeneca |
| 6765 | Dan Hanley | Johns Hopkins University | Pandemic response COVID-19 Research Collaboration Platform | NYU Grossman School of Medicine, Intermountain Healthcare, Washington University, St. Louis, Bassett Medical Center, The Queen's Medical Center, Duke University School of Medicine/Duke University Hospital, University Medical Center, New Orleans |
| 6836 | Alana Rojewski | Medical University of South Carolina | Smoking Cessation Pharmacotherapy Efficacy in Comorbid Medical Populations: Secondary Analysis of the EAGLES Randomized Clinical Trial | Pfizer Inc. |
| 6860 | Nicholas Lange | Columbia University Irving Medical Center | Belatacept in obese kidney transplant recipients | Bristol Myers Squibb |
| 6866 | Andy Lim | Monash Health | Meta-analysis of early stroke recurrence rate in minor stroke | AstraZeneca |
| 6869 | Zhen Lin | Co-founder and CEO, Robot Bacon Corporation | Evaluating Clinical trial data conventions for the Observational Medical Outcomes Partnership Common Data Model | Roche, GlaxoSmithKline, Takeda, AstraZeneca, Ferox Therapeutics |
| 6881, 5484 | Stefan Leucht | Section for Evidence-based Psychiatry, Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany | Individual-patient-data (IPD) meta-analysis of the efficacy of clozapine versus second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia | Lilly |
| 7062 | Julien Edeline | Centre Eugene Marquis | PATIENT REPORTED OUTCOME (PRO) AS A PROGNOSTIC MARKER IN PATIENTS TREATED WITH TARGETED THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA (PRO²-HCC) | Bristol Myers Squibb |
| 7070 | Georgios Tsakonas | Karolinska University Hospital/Karolinska Institutet | Anaplastic Lymphoma Kinase- Brain Prognostic Index (ALK-BPI) a novel prognostic score for brain metastasized ALK+ Non Small Cell Lung Cancer (NSCLC) | Roche |
| 7072 | James Signorovitch | Analysis Group, Inc. | Development of natural history controls to contextualize clinical trial outcomes of boys with Duchenne muscular dystrophy treated with DS-5141b | Cure Duchenne |
| 7074 | Gregory YH Lip | University of Liverpool, Liverpool, Merseyside, United Kingdom | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Boehringer Ingelheim |
| 7076 | Elias Eriksson | Dept. of Pharmacology, Inst. for Neuroscience and physiology, Sahlgrenska Academy, University of Gothenburg, Sweden | Post hoc patient-level analysis of the impact of amitriptyline, selective serotonin reuptake inhibitors, and placebo of individual items of the Hamilton Depression Rating Scale | GlaxoSmithKline |
| 7077 | Neeraj Narula | Hamilton Health Sciences | Dominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohn’s Disease | Johnson & Johnson, AbbVie |
| 7078 | Alberto Martini | University of Cincinnati | Role of Body Mass Index and concomitant medication use in metastatic urothelial carcinoma | Roche |
| 7101 | Jason Luke | University of Pittsburgh; UPMC Hillman Cancer Center | Analysis of gene expression profiles in melanoma tumors exhibiting differential lactate dehydrogenase biomarker levels and correlation with immunotherapy response | Bristol Myers Squibb |
| 7104 | Jakob Näslund | University of Gothenburg | Item-level effects of adjuvant olanzapine and/or olanzapine monotherapy in treatment-resistant depression | Lilly |
| 7126 | Alessio Cortellini | Imperial College London | The predictive role of inflammation indices in patients treated with immunotherapy or chemotherapy for advanced non-small cell lung cancer | Roche |
| 7127 | Alexa Kimball | Beth Israel Deaconess Medical Center | Effects of adalimumab on inflammation-associated hematologic abnormalities in patients with Hidradenitis Suppurativa | AbbVie |
| 7136 | Shou-Ching TANG | UMMC Cancer Center and Research Inst. | Validation of trastuzumab-emtansine (T-DM1) Toxicity Score to predict response to T-DM1 treatment in metastatic breast cancer | Roche |
| 7140 | Michael J. Sorich | Flinders University of South Australia | Early markers of clinical outcome to ipilimumab therapy for advanced melanoma | Bristol Myers Squibb |
| 7142 | Sara Tedeschi | Brigham and Women's Hospital | Causal inference cohort re-analysis of the 'CARES' trial to better understand the roles of colchicine, allopurinol, and febuxostat on cardiovascular events among patients with gout | Takeda |
| 7143 | Chaim Singal | experiMind | The effects of systemic anti-infective concomitant medications on progression of neurological diseases | GlaxoSmithKline, Lilly, Boehringer Ingelheim, UCB |
| 7144 | Timothy Perk | AIQ Solutions | External validation of the AIQ predictive score of clinical benefit using Sodium Fluoride (NaF) position emission tomography/computed tomography (PET/CT) images in metastatic prostate cancer (mPC). | Pfizer Inc. |
| 7145 | Joan Busner | Signant Health | Psychometric evaluation of PANSS in adolescent schizophrenia trials | Otsuka Pharmaceuticals |
| 7147 | Carmela Tartaglia | University of Toronto | Exploring the heterogeneity of cognitive profile in patients with Progressive Supranuclear Palsy (PSP) enrolled in the ABBV-8E12 trial and the relationship to brain volumes | AbbVie |
| 7156 | Angelina Tjokrowidjaja | University of Sydney NHMRC Clinical Trials Centre | Concordance between disease progression by Cancer Antigen 125 and computerized tomography (CT) progression in patients with relapsed advanced ovarian cancer treated with poly(adenosine diphosphate [ADP]–ribose) polymerase inhibitor: a pooled analysis | AstraZeneca |
| 7158 | Neeraj Narula | Hamilton Health Sciences | Patient Reported Symptoms as Predictors of Endoscopic Improvement in Ulcerative Colitis | Takeda |
| 7159, 6634 | James Signorovitch | Analysis Group | Associations between steroid treatment, functional outcomes and disease milestones among subgroups of patients with Duchenne muscular dystrophy (DMD) | Cure Duchenne |
| 7161 | Wesley Kerr | UCLA | Real-time monitoring of individual response to antiseizure medication treatment during clinical trials | UCB, GlaxoSmithKline, Johnson & Johnson |
| 7162 | Andrew Bottomley | European Organisation for Research and Treatment of Cancer (EORTC) | Cancer Clinical Trials Pooling of Quality Life Data (CATAPULT) initiative | Bristol Myers Squibb |
| 7163 | Laura Mezquita | Hospital Clinic and the Translational Genomics Group at IDIBAPS | Prospective validation of the Lung Immune Prognostic Index in patients with non-small cell and small cell lung cancers. | Roche, Project Data Sphere |
| 7164 | Jörg Ellinger | University Hospital Bonn, Germany | Evaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinoma | Roche |
| 7224 | Keiichi Fujiwara | Gynecologic Oncology Trial and Investigation Consortium (GOTIC) | Early prediction of survival outcome of large-scale randomized clinical trials using artificial intelligence technology | Roche, Boehringer Ingelheim, Lilly |
| 7225 | Neeraj Narula | Hamilton Health Sciences | Early vs. Delayed Response to Vedolizumab in Ulcerative Colitis | Takeda |
| 7227 | Catrin Tudur-Smith | University of Liverpool | Add-on treatment for refractory focal-onset epilepsy: Individual Participant Data Network Meta-analysis | UCB, GlaxoSmithKline, Johnson & Johnson |
| 7232 | Neil Oxtoby | University College London | Identification of heterogeneity in Alzheimer’s disease clinical trials using computational modelling | Takeda |
| 7241 | Frederick Reimherr | Psychiatric and Behavioral Solutions, LLC | Retrospective Analysis of Emotional Symptoms in Adults with ADHD and Improvement Produced by Brexpiprazole | Otsuka Pharmaceuticals |
| 7243 | Emanual Maverakis | University of California Davis | Developing Models from Existing Atopic Dermatitis Outcome Data | GlaxoSmithKline |
| 7245 | Manabu Takaki | Okayama University | Clinical moderators of response to nalmefene in alcohol dependence: Results from a randomized controlled trial in Japan. | Otsuka Pharmaceuticals |
| 7274 | Jun Chen | West China Hospital, Sichuan University | Efficacy comparision of biologics (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) in treatment of severe eosinophilic asthma -- a network meta-analysis | GlaxoSmithKline |
| 7277 | Eric Harvey | MMS Holdings | Integrating clinical data from 2 trials into the International COVID-19 Data Alliance (ICODA) Workbench | Roche |
| 7283 | Franziska Michor | Dana-Farber Cancer Institute/Harvard University | Large-scale public data reuse to model immunotherapy response and resistance | Bristol Myers Squibb |
| 7288 | Vipual Jairath | Alimentiv Inc | Placebo Rates in Inflammatory Bowel Disease: An Individual Patient Data Meta-analysis of Randomized Controlled Trials | AbbVie, Takeda, Johnson & Johnson |
| 7289 | Gianluca Rigatelli | Ausl5, Rovigo General Hospital | Outcomes of Left Main Purcutaneous Coronary Intervention (PCI) across age classes | Duke University School of Medicine/Duke University Hospital |
| 7312 | Marianna Kruithof-de Julio | DEPARTMENT FOR BIOMEDICAL RESEARCH (DBMR), UNIVERSITY OF BERN, AND UNIVERSITY HOSPITAL FOR UROLOGY, INSELSPITAL BERN | Machine learning for personalized drug response prediction for bladder and prostate cancer patients | Tempus AI, Inc. |
| 7317 | Emanual Maverakis | University of California Davis | Developing Efficacy Assessment Tools from Existing Psoriasis Clinical Trial Outcome Data | Lilly |
| 7321 | Neeraj Narula | Hamilton Health Sciences | A Comparison of the Rapidity of Clinical Response between Infliximab and Tofacitinib for Ulcerative Colitis | Pfizer Inc., Johnson & Johnson |
| 7322 | Zhengfei ZHU | Fudan University Shanghai Cancer Center | Clinical value and optimal candidate of cranial radiotherapy in atezolizumab-treated advanced non-small cell lung cancer with baseline brain metastasis | Roche |
| 7323 | Toshifumi Kishimoto | Nara Medical University | Development of the optimal treatment of Nalmefene in patients with alcohol dependence | Otsuka Pharmaceuticals |
| 7325 | Andreas Artemiou | Cardiff University | Predicting outcomes (death, survival) of COVID-19 patients on Standard of Care (SoC) . | Roche, NYU Grossman School of Medicine, University Medical Center, New Orleans |
| 7379 | Michele Romoli | Bufalini Hospital | Antithrombotics in patent formane ovale (PFO)-related stroke: a meta-analysis stratified for the risk of paradoxical embolism score (RoPE) | Boehringer Ingelheim |
| 7381 | Tomoya Hirota | University of California San Francisco | Early Prediction of Treatment Response to Antipsychotics for Irritability and Aggression in Autism Spectrum Disorder | Otsuka Pharmaceuticals, Johnson & Johnson |
| 7384 | Ulrich Mansmann | Department for Medical Information Processing, Biometry, and Epidemiology; Ludwig-Maximilian’s University München; Marchioninistrasse 15 D-81377 München | Application of Estimands and Causal Reasoning in the Reanalysis of Endpoint Measures in Advanced/Metastatic Non-Small Cell Lung Cancer Clinical Trials | Takeda, Roche, AstraZeneca |
| 7387 | Neeraj Narula | Hamilton Health Sciences | Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn’s Disease | Takeda, AbbVie, Johnson & Johnson |
| 7388 | Byeongzu Ghang | Division of Rheumatology, Jeju National University School of Medicine, Jeju National University Hospital | Reanalysis of CARES study to investigate the changes of estimated glomerular filtration rate after long-term febuxostat or allopurinol treatment in gout patients | Takeda |
| 7394, 6117, 5895 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers_092021 | Roche |
| 7395 | Xiaoling Shang | Shandong University | Survival analysis of advanced lung adenocarcinoma harboring epidermal growth factor receptor gene mutation receiving the combination treatment of atezolizumab, bevacizumab, carboplatin and paclitaxel. | Roche |
| 7396 | Mary Ann Lukas | GlaxoSmithKline | Modeling and Simulation of ambrisentan pharmacokinetics in young children | Duke University School of Medicine/Duke University Hospital |
| 7399 | Yoichi Naito | National Cancer Center East | Combined analysis of randomized phase III study ANNOUNCE and randomized phase II study exploring olaratumab. | Lilly |
| 7400 | Aryelly Rodriguez | The University of Edinburgh | What are the re-identification risk scores of publicly available anonymised clinical trial datasets? | GlaxoSmithKline, UCB |
| 7401 | Scott Garrison | Faculty of Medicine and Dentistry, University of Alberta | Randomized Controlled Trial Data Availability and Re-Analysis Project | Roche, University of Washington, Pfizer Inc. |
| 7404 | Reena Khanna | Lawson Health Research Institute | A Study to Assess the Correlation Between Harvey Bradshaw Index and Patient Reported Outcome 2 in Crohn's Disease Patients Enrolled in Large Scale Randomized Controlled Trials | Takeda |
| 7414 | Nobuyuki Horita | Chemotherapy Center, Yokohama City University Hospital | Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Trials Evaluating Atezolizumab Regimens for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma | Roche |
| 7427 | Joachim Tan | Monash University | Dose reduction and discontinuation of disease modifying anti-rheumatic drugs (DMARDs) for juvenile idiopathic arthritis | AbbVie, Johnson & Johnson, Roche |
| 7435 | Noah Goldfarb | University of Minnesota | Decision tool for the use of adalimumab for hidradenitis suppurativa | AbbVie |
| 7445 | Catherine Thieblemont | Inserm | Evaluation of surrogate markers in marginal zone lymphoma | Roche |
| 7462 | Junjie Zhuo | Hainan University | Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles with Clinical Profiles in the Progression of Alzheimer’s Disease | AstraZeneca |
| 7492 | Yang Zhao | Nanjing Medical University | An Investigation on the Role of Blood Biomarkers as Predictors for Individualized Treatment Regimen Selection in Non-Small Cell Lung Cancer. | Roche |
| 7493 | Nina Hilkens | Radboudumc Nijmegen | Blood pressure variability and progression of white matter hyperintensities after ischemic stroke | Boehringer Ingelheim |
| 7495 | Thomas Antalffy | Smart Respiratory Products Ltd | Analysing Clinical Applicability of CompEx Endpoints | AstraZeneca |
| 7498 | Riccardo Polosa | Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), University of Catania | A Machine Learning approach to improve smoking cessation trials | Pfizer Inc. |
| 7501 | Min-Gul Kim | Jeonbuk National University Hospital | COVID-19 clinical trial data utilization to develop external control datasets in COVID-19 therapeutics development | Hospital Universitario Austral, Montreal Heart Institute, University of Minnesota, Lilly, Roche, HCor Research Institute |
| 7503, 6635 | Leslie Padrnos | Mayo Clinic Arizona | systematic review and meta-analysis Heme Malignancy VTE anticoagulation | Boehringer Ingelheim, Pfizer Inc., Daiichi Sankyo, Inc. |
| 7518 | Lucio Manenti | UNIVERSITY HOSPITAL OF PARMA | Role of persistent and isolated reduced serum complement 3 (C3) in lupus nephritis | Roche |
| 7520 | Malathi Ram | Johns Hopkins Bloomberg School of Public Health | ACEi/ARB medications for hospitalized patients with COVID-19 – an individual patient data (IPD) based pooled analysis | University of Kansas Medical Center, Sharp Healthcare, University of Minnesota, Bassett Medical Center |
| 7535 | Joshua Drago | Memorial Sloan Kettering Cancer Center | Statin use and clinical outcomes on ado-trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer | Roche |
| 7539 | Amit Etkin | Alto Neuroscience, Inc. | Clinical and demographic predictors of antidepressant treatment in patients with major depressive disorder with agomelatine versus vortioxetine | Lundbeck |
| 7541 | Amit Etkin | Alto Neuroscience, Inc | Role of clinical, historical and demographic factors in the response to antidepressants versus placebo | Lilly, Takeda |
| 7542 | Neeraj Narula | Hamilton Health Sciences | Vedolizumab vs. Adalimumab in Ulcerative Colitis: Validation of Indirect Comparisons | AbbVie, Takeda |
| 7543 | Margaret Salisbury | Vanderbilt University Medical Center | Disease progression modeling to detect treatment effects in pulmonary fibrosis | Roche, Boehringer Ingelheim |
| 7544 | Cynthia Comella | Rush University Medical Center | Sensory trick and benefit from botulinum toxin in cervical dystonia | AbbVie |
| 7549 | Vipul Jairath | Alimentiv Inc. | Responsiveness of the UC-100 Score in Patients with Moderately to Severely Active Ulcerative Colitis | AbbVie, Takeda, Johnson & Johnson |
| 7552 | Anna van Eijk | Liverpool School of Tropical Medicine | Impact of Malaria in Pregnancy on Infants Study Group | Pfizer Inc. |
| 7580 | Hiroyoshi Takeuchi | Department of Neuropsychiatry, Keio University School of Medicine | Effects of gaps in doses between oral and long-acting injectable aripiprazole on clinical outcomes in schizophrenia | Otsuka Pharmaceuticals |
| 7581 | Rustam Al-Shahi Salman | University of Edinburgh | Collaboration Of Controlled Randomised trials of Oral Antithrombotic agents after intraCranial Haemorrhage (COCROACH) | Daiichi Sankyo, Inc. |
| 7583, 5932 | Youssef Zeidan | American University of Beirut | Evaluation of Radiotherapy after Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients | Roche |
| 7587 | Yashmin Karten | Critical Path Institute | Model-Informed Drug Development (MIDD) in Alzheimer's Disease | Lilly |
| 7590 | Noémie Lang | University Hospitals of Geneva (HUG) | FRILLY: a retrospective single center study on Fractionated Rituximab to avoid Lysis Syndrome in Aggressive B-Lymphoma | Roche, Project Data Sphere |
| 7591, 7392 | Neeraj Narula | Hamilton Health Sciences | Predictors of Placebo Response and Remission in Ulcerative Colitis and Crohn’s Disease VERSION 2.0 | AbbVie, Takeda, Johnson & Johnson, Pfizer Inc. |
| 7592 | Alexandre Betourne | Critical Path Institute | Integration of Biogen Rare Disease Data into RDCA-DAP | Biogen |
| 7595 | Ashley Hopkins | Flinders University | Predicting therapeutic outcomes to immune checkpoint inhibitors used in cancer treatment_012022 | Roche |
| 7597 | Junko Takeshita | University of Pennsylvania | Evaluating Racial and Ethnic Differences in the Quality-of-Life Impact of Atopic Dermatitis | Regeneron, Pfizer Inc., Lilly |
| 7598 | Harry Southworth | Data Clarity Consulting Ltd | Statistical investigation of comorbidities of back pain in the medical history data from clinical trials of healthy subjects | GlaxoSmithKline, AstraZeneca |
| 7599 | Hwanhee Hong | Duke University | Combining data sources to identify effect moderation for personalized mental health treatment | Johnson & Johnson, Takeda, Lundbeck |
| 7601 | Guru Sonpavde | AdventHealth Cancer Institute, Orlando, Florida | Mathematical prognostic model utilizing multi-platform dynamics in patients with metastatic urothelial carcinoma receiving post-platinum immune checkpoint inhibitors | Roche |
| 7606 | Amber Salter | UT Southwestern Medical Center | Comorbidity and Clinical Trials of Disease-Modifying Therapies in Multiple Sclerosis | Roche |
| 7609 | Joao Pedro Ferreira | Porto University | The impact of albiglutide on heart failure outcomes among patients with type 2 diabetes with and without heart failure at baseline | GlaxoSmithKline |
| 7620 | Emilie Sbidian | University Paris Est Creteil (UPEC) | Systemic pharmacological treatments for chronic plaque psoriasis: A Systematic Review and an Individual-Patient Data Network Meta-Analysis of Randomized Controlled Trials | AbbVie, Lilly, Pfizer Inc., Johnson & Johnson, UCB |
| 7621 | Adam Boxer | UCSF | Bayesian Disease Progression Modeling and Clinical Trial Design for Progressive Supranuclear Palsy - Richardson's Syndrome | AbbVie |
| 7654 | Shirley Yu | Institute of Bone and Joint Research, University of Sydney Department of Rheumatology, Royal North Shore Hospital. Sydney, Australia | Update of individual data meta-analysis of intra-articular corticosteroids in knee and hip osteoarthritis | Sanofi |
| 7656 | Neeraj Narula | Hamilton Health Sciences | Impact of Steroid Weaning Regimens on Outcomes in Clinical Trials of Ulcerative Colitis | Johnson & Johnson, AbbVie, Takeda, Pfizer Inc. |
| 7658 | Arman Sabbaghi | Statistics, Purdue University | Tripartite Estimands for Adherence Causal Inference in Clinical Trials, With Applications for the Development of COVID-19 Treatments | Sanofi |
| 7660 | Shirley Yu | Institute of Bone and Joint Research, University of Sydney Department of Rheumatology, Royal North Shore Hospital. Sydney, Australia | Predictors of placebo response to intra-articular therapy in osteoarthritis - an individual patient data meta-analysis | Sanofi |
| 7661 | Baocheng Chang | Chu Hsien-I Memorial Hospital, Tianjin Medical University | Effects of Lixisenatide on the primary prevention of diabetic kidney disease in population with high risk | Sanofi |
| 7662 | Benoit You | Université Claude Bernard Lyon | Prognostic And Predictive Value Of The Modeled PSA Kinetics Parameters In Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel Or Cabazitaxel (Phase III Trial — FIRSTANA) | Sanofi |
| 7663, 7385 | Amit Etkin | Alto Neuroscience, Inc. | Cognition and clinical factors as predictors of antidepressant treatment outcome in patients with major depressive disorder | Takeda, Lundbeck, Lilly |
| 7667 | Ashley Hopkins | Flinders University | Summarising the therapeutic and adverse effects of anticancer medicines according to race and sex: pooled analysis of clinical trials of contemporary treatments for solid tumours | AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Inc., Lilly, Roche, Pfizer Inc., Sanofi, Takeda, Johnson & Johnson, Bayer |
| 7743 | Caroline Quach | CHU Sainte-Justine | Is there a Difference in the Immune Response, Efficacy, and Safety of Seasonal Influenza Vaccine in Males and Females? - A Meta-Analysis. | Sanofi |
| 7758 | NAHID SULTANA | University of Sheffield | Indirect comparisons of time-to-event outcomes using single-arm studies in health technology assessment (Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma) | GlaxoSmithKline |
| 7759 | Tamar Oostrom | The Ohio State University | Heterogenous Effects in Diabetes Mellitus Clinical Trials and Implications for Physician Prescriptions | Sanofi, GlaxoSmithKline |
| 7760 | John (Devin) Peipert | Northwestern University | Study of Functional Assessment of Chronic Illness Therapy (FACIT) GP5 Item as a Measure of Treatment Tolerability in Advanced Cancer Patients across Multiple Tumour Sites and Treatment Types | Roche, Lilly, Pfizer Inc. |
| 7772 | Neeraj Narula | Hamilton Health Sciences | Combined Histologic and Endoscopic Endpoints in Ulcerative Colitis | Takeda |
| 7776 | Stefan Leucht | Professor Stefan Leucht MD. Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany | Antipsychotic drugs vs. placebo in the treatment of antipsychotic naive and/or first episode children or adolescents with psychosis: A systematic review and meta-analysis of double-blind randomized trials | Lilly, Otsuka Pharmaceuticals |
| 7777 | PAUL AYUK | Newcastle-upon-Tyne Hospitals NHS Trust | Using Dabigatran etexilate to prevent blood clots in women after childbirth | Boehringer Ingelheim |
| 7779 | Luís Inês | 1- Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal | Derivation and validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) severe disease activity category: post-hoc analysis of the anifrolumab clinical trials in active systemic lupus erythematosus. | AstraZeneca |
| 7782 | Yang Li | Renmin University of China | A new covariate randomization method for multi-arm randomized controlled trials | GlaxoSmithKline |
| 7785 | Christian Jonasson | NordicRWE | Using Norwegian real world data to emulate and reproduce results from oncology clinical trials | Roche |
| 7794 | Joan CARLES | VALL D HEBRON INSTITUTE OF ONCOLOGY VALL D'HEBRON UNIVERSITY HOSPITAL Passeig Vall d'Hebron 119-129 08035 BARCELONA | Co Medication (aspirin, statins and metformin) analysis in patients with metastatic Castration Resistant Prostate Cancer treated with Chemotherapy. | Sanofi |
| 7797 | Jörg Ellinger | Department of Urology, University Hospital Bonn, Germany | Evaluation of the performance of the modified Glasgow prognostic score in urothelial carcinoma, non-small cell lung cancer and renal cell carcinoma | Roche, Pfizer Inc., Project Data Sphere |
| 7801, 6864 | Yoshie Omachi | National Center of Neurology and Psychiatry (NCNP) | Elucidation of the predictive factors for active and placebo drug response on social functioning and quality of life (QOL) in psychiatric illnesses including developmental disorders | Lilly, Johnson & Johnson, Shionogi |
| 7804 | Qingyun Li | Genecast Biotechnology Co., Ltd | An exploratory study of the fusion co-mutated immune microenvironment in Non-small cell lung cancer | Roche |
| 7807 | Hayato Niiyama | School of Data Science, Yokohama City University, Japan | A Post-hoc Analysis using Secondary Data of Clinical Trial from M14-033 Study to Evaluate Average Treatment Effect and Heterogeneous Treatment Effect of Adalimumab in Maintenance Phase for Patients with Ulcerative Colitis | AbbVie |
| 7809 | David James Pinato | Imperial College, London | The prognostic impact of early antibiotics exposure on Overall Survival and Progression Free Survival of patients affected by unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab or sorafenib within the IMbrave 150 trial | Roche |
| 7810 | Diego Chowell | Icahn School of Medicine at Mount Sinai | Machine learning model to predict cancer immunotherapy response | Roche |
| 7811 | Gustavo Turecki | Douglas Mental Health University Institute, McGill University | Using Artificial Intelligence to Personalize Treatment Selection and Trajectory Monitoring of Bipolar Disorder | Lilly, AbbVie, Takeda, Otsuka Pharmaceuticals |
| 7817 | Neeraj Narula | Hamilton Health Sciences | Predictors of Histologic Response using Antibodies Against Interleukin-5 in Eosinophilic Esophagitis | GlaxoSmithKline |
| 7818 | Werner Weitschies | University of Greifswald, Center ofDrug Absorption and Transport | Development and improvement of an in vitro tool, which simulates the physiological characteristics of the ascending colon | Sanofi |
| 7819 | Jeanine Roeters van Lennep | Erasmus University Medical Center | Efficacy & Safety of Proprotein Convertase Subtilisin/Kexin type 9 Inhibitors: a Systematic Review and Meta-analysis of Real-World Data | Sanofi |
| 7822 | Linbin Lu | the 900th Hospital of PLA | Trajectories of alpha-fetoprotein and liver cancer outcomes after atezolizumab treatment | Roche |
| 7823 | Marc Carrier | University of Ottawa | Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Patients with Cancer: A Systematic Review | GlaxoSmithKline, Sanofi |
| 7824 | Feng Sun | Peking University | An individual participant data meta-analysis to evaluate PD1 vs PD-L1 Inhibitors in Asian subgroup Cancer patients | Daiichi Sankyo, Inc., Roche |
| 7828 | Sofia Ramiro | Leiden University Medical Center | SPondyloarthritis: EARly Definition (ASAS-SPEAR): Analysis of Symptom Duration Thresholds Using Pooled Data from Randomized Controlled Trials | Lilly, Pfizer Inc., UCB, AbbVie, Johnson & Johnson |
| 7830 | Yi-Wen Tsai | Institute of Health & Welfare Policy, National Yang Ming Chiao Tung University, Taiwan | Cost effectiveness analysis of atezolizumab plus chemotherapy for untreated extensive stage small cell lung cancer in Asia | Roche |
| 7835 | Hiroyuki Kusuhara | The University of Tokyo | Assessment of the drug-drug interactions risks of drugs based on the clinical data of the plasma biomarkers | AbbVie |
| 7840 | Marco Tagliamento | IRCCS Ospedale Policlinico San Martino | Clinical Effect of Chemotherapy-Immunotherapy Combination in the First-Line Treatment of Older Patients with Non-Small Cell Lung Cancer | Roche |
| 7842 | Marco Tagliamento | IRCCS Ospedale Policlinico San Martino | Pooled Efficacy and Safety Analysis of the Phase III Studies of Alectinib vs. Crizotinib in Untreated ALK-Positive Non-Small Cell Lung Cancer | Roche |
| 7844 | Linong Ji | Peking University People's Hospital | Risk stratification and responder identification using a baseline model and a dynamic risk prediction model for GLP-1RA and SGLT2i in T2DM: a machine learning facilitated posthoc analysis of CVOTs | GlaxoSmithKline, BioLINCC (a data-sharing platform funded by the National Institutes of Health), Johnson & Johnson |
| 7845 | Craig Nelson | University of California San Francisco | Change in cognition during antidepressant treatment of late life depression | Lilly, Lundbeck |
| 7846 | Samuele Cortese | University of Southampton, UK | PATIENCE Individual Patient DATa Network Meta-AnalysIs of the Efficacy aNd aCceptability of Attention-Deficit/Hyperactivity Disorder (ADHD) mEdication | AbbVie, Johnson & Johnson, Lilly, Takeda |
| 7848 | Jennifer Lund | Department of Epidemiology, University of North Carolina at Chapel Hill | Improving Colon Cancer Therapy Decisions by Extending Trial Representation | Sanofi |
| 7849 | Igor Stojkov | Paul-Ehrlich-Institut | Determinants of study design for vaccines against opportunistic bacterial infections: a proof-of-concept for data-driven, individual patient data (IPD) analyses. | Sanofi |
| 7850 | Vipul Jairath | Departments of Medicine (Division of Gastroenterology) and cross-appointment to Epidemiology and Biostatistics at The University of Western Ontario | Impact of concomitant baseline medication, advanced age and racial differences on efficacy of biologics and small molecules for Inflammatory Bowel Disease | Johnson & Johnson, Takeda, UCB, Pfizer Inc., AbbVie |
| 7854 | Vipul Jairath | Departments of Medicine (Division of Gastroenterology) and cross-appointment to Epidemiology and Biostatistics at The University of Western Ontario | Efficacy of medical therapies for ulcerative colitis according to disease distribution: An individual patient data meta-analysis of randomized controlled trials | Pfizer Inc., Johnson & Johnson, AbbVie, Takeda |
| 7856 | Evandro de Azambuja | Institut Jules Bordet, Brussels, Belgium | Metastatic HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab: the impact of early response on patient survival | Roche |
| 7857 | Rentao Yu | the First Affiliated Hospital of Chongqing Medical University | Cutaneous immune-related adverse events of immunotherapy medications in the treatment of cancers and association with survival. | Roche, Daiichi Sankyo, Inc. |
| 7858 | Jie Zha | Department of Hematology, The First Affiliated and Institute of Hematology, School of Medicine, Xiamen University | Retrospective cohort study with internal and external validation of a predictive tool for POD24 risk assessment in follicular lymphoma patients | Roche |
| 7860 | Kemi Williams | 54gene | UNITY Global Study Nigeria Datasets | Certara |
| 7868 | Anne-Marie Dingemans | Erasmus MC University Medical Center | Predictive clinical characteristics for weight gain in patients treated with alectinib | Roche |
| 7872 | Dorra Bouazzi | Department of Dermatology, Zealand University Hospital | Hidradenitis Suppurativa – a collaborative study of subtypes | AbbVie |
| 7873 | Xue Yang | Beijing Cancer Hospital | Crizotinib followed by alectinib vs alectinib alone: analysis of treatment-naïve patients with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) -rearrangement | Roche |
| 7874 | Chiara Alessandra Cella | Istituto Europeo di Oncologia | Addressing the synergistic effect of metformin in patients with Pancreatic neuroendocrine tumors treated with sunitinib: a post-hoc analysis from the main pivotal trials. | Pfizer Inc. |
| 7875 | Marco Valgimigli | Cardiocentro Ticino, Lugano and Universita della Svizzera ltaliana (USI) | P2Y12 inhibitor or Aspirin moNoTHERapy as secondary prevention in patients with coronary artery disease: in individual patient data meta-analysis (PANTHER collaborative initiative) | Sanofi |
| 7882 | José González-Gomariz | FIMA | Study of the expression of several cytokines related with the survival in cancer melanoma patients | Bristol Myers Squibb |
| 8052 | Wataru Fukuokaya | The Jikei University School of Medicine | Association of serum magnesium levels with the effectiveness of atezolizumab in advanced urothelial carcinoma | Roche |
| 8053 | Alexander G Mathioudakis | Manchester University NHS Foundation Trust | ICS-RECODE: Predictors of treatment REsponse to inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease: randomised COntrolled trials individual participant Data re-Evaluation. | GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca |
| 8056 | Ashley Hopkins | Flinders University | Summarising the therapeutic and adverse effects of antibody-drug conjugates in older women with breast cancer: A review of avaliable clinical trial individual-participant data | Roche |
| 8058 | Howard Smith | Pulmonary Vascular Disease Unit, Royal Hallamshire, Sheffield Teaching Hospitals | An individual patient data meta-analysis of clinical endpoints in pulmonary hypertension with interstitial lung disease (PH-ILD) | Boehringer Ingelheim, Johnson & Johnson |
| 8175 | Guoxing Wan | Hubei University of Medicine | Efficacy and safety of atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade | Roche |
| 8180 | Sheng Luo | Duke University | Clinical and molecular characteristics of human epidermal growth factor receptor 2-positive and human epidermal growth factor receptor 2-negative breast cancer | Daiichi Sankyo, Inc., Roche, Lilly, Pfizer Inc. |
| 8236 | Gao-Jun Teng | Zhongda Hospital, Southeast University | The role of prior transarterial chemoembolization in atezolizumab plus bevacizumab in hepatocellular carcinoma | Roche |
| 8244 | Frank Doyle | Royal College of Surgeons Ireland | Do psychometrics matter? The effects of advanced psychometric analyses on depression randomised trial outcomes | GlaxoSmithKline, Lilly, Pfizer Inc., Takeda |
| 8263 | George Ntaios | University of Thesaly, Larissa, Greece | Risk of myocardial infarction in patients with paroxysmal vs. non-paroxysmal atrial fibrillation: an individual patient data meta-analysis | Boehringer Ingelheim, Daiichi Sankyo, Inc. |
| 8266 | Shenghong Zhang | The first affiliated hospital of Sun Yat-sen University | The prognostic value of faecal calprotectin for long-term outcomes in ulcerative colitis | Takeda |
| 8287 | Damian J. Ralser | Department of Gynecology and Gynecological Oncology, University Medical Center Bonn (UKB), Bonn, Germany & Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany | Evaluation of the easy-to-implement modified Glasgow prognostic score (mGPS) in patients with previously treated human epidermal growth factor receptor 2-positive advanced breast cancer in the KATE2 clinical trial | Roche |
| 8294 | Neeraj Narula | Hamilton Health Sciences | Extended Validation of an Ulcerative Colitis Vedolizumab Decision Support Tool for Outcome Prediction with Tofacitinib | Pfizer Inc. |
| 8315 | Chiara Tani | Azienda Ospedaliero Universitaria Pisana, University of Pisa | Evaluation of gender differences in the efficacy and safety of belimumab in the treatment of active systemic lupus erythematosus | GlaxoSmithKline |
| 8316 | Vipul Jairath | Alimentiv | Correlation Between Symptoms and Objective Measures of Disease Activity in Patients with Moderate to Severe Ulcerative Colitis and Crohn’s Disease | Pfizer Inc., Takeda, Johnson & Johnson, AbbVie |
| 8324 | Jeroen Dekervel | UZ Leuven, Leuven, Belgium | Response Evaluation Criteria in Solid Tumors (RECIST) vs modified RECIST response durability in advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab | Roche |
| 8325 | Xiaodan Tang | Northwestern University | Does scoring method impact estimation of significant individual changes using Patient-Reported Outcomes Measurement Information System (PROMIS) measures? Comparing Classical Test Theory versus Item Response Theory | AbbVie |
| 8327 | Eva Hoster | Department for Medical Information Processing, Biometry, and Epidemiology Ludwig-Maximilian University (LMU) Munich | Constructing estimands for overall survival within causal frame work for dynamic treatment schemes in oncology: Simulation and a clinical trial example | Roche |
| 8342, 7444 | GUS SLOTMAN | INSPIRA HEALTH NETWORK, VINELAND, NJ | IDENTIFYING TOCILIZUMAB-RESPONSIVE COVID-19 PATIENTS FROM COVACTA, EMPACTA, AND REMDACTA RCTS PRE-RANDOMIZATION DATA | Roche |
| 8344 | Xiaoling Shang | Shandong University | A clinical variable based-Nomogram could predict survival for Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide | Roche |
| 8347 | Hong Jae Chon | CHA Bundang Medical Center | Thyroid irAE correlated with favorable clinical outcome in patients with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab | Roche |
| 8349 | Nqoba Tsabedze | University of Witwatersrand | The efficacy of beta-blockers on morbidity and mortality endpoints in black hypertensive patients: A meta-analysis | GlaxoSmithKline |
| 8377 | Neeraj Narula | Hamilton Health Sciences | Estimating Differences in the Comparison of Outcomes in Clinical Trials for UC Patients using Patient-Level Data and Aggregated Data: Network Meta-Analysis | Takeda, Johnson & Johnson, Pfizer Inc., AbbVie |
| 8427 | Ahmad Abuhelwa | University of Sharjah | Predictors of exposure, therapeutic and adverse effects of medicines used in the treatment of multiple myeloma | Sanofi, Takeda, Johnson & Johnson |
| 8435 | Hui Zheng | Chengdu University of Traditional Chinese Medicine | Predictors of galcanezumab in the preventive treatment of migraine | Lilly |
| 8436 | David Schade | NM Non profit Society to Prevent Symptomatic Heart Disease | Development of an Atherosclerosis Reversal Calculator | AstraZeneca |
| 8438 | Sheng Luo | Duke University | Development of novel statistical methods to detect treatment effect in Alzheimer’s disease clinical trials over time | AbbVie |
| 8440 | David Seiffge | Insel Gruppe AG | Andexanet alfa and the risk of haematoma expansion in patients with non-traumatic intracerebral haemorrhage – a pooled individual patient data analysis of ANNEXA-4 ICH and TICH-NOAC | AstraZeneca |
| 8442 | Yi Lisa Hwa | Mayo Clinic | Better outcomes among multiple myeloma patients who are taking beta-blockers while receiving chemotherapy | Sanofi |
| 8443 | Lane Desborough | Nudge BG, Inc. | Aerobic and Anaerobic Exercise Effects on Blood Glucose and Insulin | Jaeb Center for Health Research Foundation, Inc. |
| 8445 | Kelley Kidwell | University of Michigan | Use of external control with longitudinal data for drug evaluation in Duchenne muscular dystrophy: a Bayesian small sample, sequential, multiple assignment randomized trial design (snSMART) | Cure Duchenne, Lilly |
| 8446, 7479, 7075 | Elias Eriksson | Neuroscience and physiology | Efficacy of serotonin reuptake inhibitors in children and adolescents #3 | Lilly, GlaxoSmithKline, Pfizer Inc., AbbVie, Lundbeck |
| 8450 | Dennis McGonagle | Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds, UK | The effect of Body Mass Index (BMI) and Age on Baricitinib efficacy in Covid-19 patients | Lilly |
| 8542 | João Sérgio Neves | Faculty of Medicine of University of Porto | Albiglutide and Cardiovascular Outcomes in Type 2 Diabetes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use | GlaxoSmithKline |
| 8546 | Alice Adenis | Diabeloop | Modeling the impact of physical activity, estimated by sensors such as accelerometers and heart rate, on glycemia of Type 1 Diabetes (T1D) patients. | Jaeb Center for Health Research Foundation, Inc. |
| 8555 | Gijsbert Stoet | University of Essex, Colchester, UK | Effects of exercise on blood glucose levels, food intake and insulin use in T1D patients | Jaeb Center for Health Research Foundation, Inc. |
| 8557 | Fan Ge | Guangzhou Medical University | Organ-specific metastatic landscape dissects programmed death ligand-1 (PD-L1) blockade efficacy in advanced cancer | Roche, Lilly |
| 8558 | Pablo Guisado Vasco | Hospital Universitario Quironsalud Madrid; Universidad Europea (Madrid) | Investigating the impact of antibodies against SARS-CoV-2 on the effectiveness of interleukin-6 inhibitors in Covid-19 patients | Roche |
| 8559 | Dag Aarsland | King's College London | Predicting Cognitive Abilities and Treatment Outcome of Major Depressive Disorder in Elderly Patients Using Vortioxetine and Duloxetine Antidepressants | Lundbeck |
| 8560 | Emily Fox | Stanford University | Hybrid machine learning modeling of Insulin-Glucose dynamics for T1D | Jaeb Center for Health Research Foundation, Inc. |
| 8562 | Raquibul Hannan | UT Southwestern Medical Center | Long-term outcomes of renal cell carcinoma patients with stable disease following treatment with Ipilimumab and Nivolumab in randomized controlled trial Checkmate 214 | Bristol Myers Squibb |
| 8564 | SANGWOO KIM | Yonsei Univ. College of Medicine | Development of Immune Phenotype-specific Immune Checkpoint Inhibitor Response (anti-programmed death ligand-1) Prediction Algorithm | Bristol Myers Squibb |
| 8569 | GUS SLOTMAN | Inspira Health Network, Vineland, NJ | USING PRE-RANDOMIZATION DATA TO IDENTIFY PATIENTS WITH COVID-19 AMONG WHOM FLUVOXAMINE OR IVERMECTIN IMPROVED OUTCOMES | Platform Life Sciences |
| 8576 | Dafne Capelusnik | Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands | Validating a Personalised Ankylosing Spondylitis Metrology Index | AbbVie, Johnson & Johnson, Pfizer Inc., UCB, Lilly |
| 8577 | Yao Zhu | Fudan University Shanghai Cancer Center | The impact of long-term proton pump inhibitors use on the prognosis of patients receiving Androgen-annihilation therapy | Bayer |
| 8581 | Masahiro Takeuchi | The University of Tokyo | Repositioning of neurological drug Aripiprazole for Amyotrophic lateral sclerosis (ALS) patients | Otsuka Pharmaceuticals |
| 8582 | David Cherney | University Health Network | Modelling Studies to Assess Sodium-Glucose co-Transporter-2 (SGLT2) Inhibition Effects and Kidney Protection in Type 1 Diabetes | AstraZeneca, Boehringer Ingelheim |
| 8585 | Daniel Schachter | Unigranrio | Efficacy of CGRP monoclonal antibodies in the treatment of medication overuse headache in patients with chronic migraine: A systematic review and meta-analysis | Lilly, Lundbeck |
| 8588 | Wenlong Zhong | Sun Yat-sen Memorial Hospital of Sun Yat-sen University（SYSU） | The influence of antibiotics on survival outcomes for bladder cancer patients being treated with immune checkpoint inhibitor therapy | Roche |
| 8591 | John Reynolds | University of Birmingham | Patterns of skin flare in patients with systemic lupus erythematosus | AstraZeneca |
| 8593 | Hyon Choi | Massachusetts General Hospital | Serum urate reduction, gout flares and risk of major cardiovascular events during urate-lowering therapy initiation: target trial emulation and self-controlled case series analysis | Takeda |
| 8599 | Marliese Alexander | Peter MacCallum Cancer Centre | Clinical factors predictive of survival outcomes in patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer | Takeda, Roche, Pfizer Inc. |
| 8602 | Robert Hamilton | Princess Margaret Cancer Center, University of Toronto | Statin use and prostate cancer outcomes in patients treated in the ARAMIS trial | Bayer |
| 8603 | Wencai Jiang | Chengdu Second People's Hospital | Predictive value of high‐sensitivity cardiac troponin‐T for Major Adverse Cardiovascular Events in patients with Chronic coronary heart disease | GlaxoSmithKline |
| 8606 | Daria Igudesman | AdventHealth Translational Research Institute | Eating duration, frequency, and distribution of nutrient intake in association with glycemia, adiposity, and sleep | Jaeb Center for Health Research Foundation, Inc. |
| 8609 | Fredrik Schjesvold | Oslo University Hospital | Personalized prediction of progression-free survival in multiple myeloma patients treated with isatuximab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone only, using combined machine learning and mechanistic modeling. | Sanofi |
| 8611 | Adam de Havenon | Yale University | Index Stroke Severity in Secondary Prevention Trials | Boehringer Ingelheim |
| 8615 | Monia Rekik | Université Laval | Using artificial intelligence to predict and prevent physical activity induced hypoglycemia and hyperglycemia in type 1 diabetes | Jaeb Center for Health Research Foundation, Inc. |
| 8656 | Meg Jardine | The University of Sydney | The RAAS inhibition in COVID-19 Trialists Collaboration | University of Minnesota, Bassett Medical Center |
| 8684 | José da Silva | Centro Hospitalar e Universitário de Coimbra | 3Variable and 4Variable Boolean-based remission with Tofacitinib and their association with radiographic outcomes in rheumatoid arthritis | Pfizer Inc. |
| 8686 | Andrea E. van der Meulen - de Jong | Leiden University Medical Center | Anemia and therapy with Janus Kinase Inhibitors in patients with ulcerative colitis | Pfizer Inc. |
| 8688 | Grace Lu-Yao | Thomas Jefferson University | Risk of therapy-related adverse events in men on abiraterone or enzalutamide, a IPD meta-analysis of clinical trial data | GlaxoSmithKline, Sanofi, Johnson & Johnson |
| 8699 | Niklas Klümper | Department of Urology and Pediatric Urology, University Medical Center Bonn (UKB) | Evaluation of baseline and on-treatment serum biomarkers to predict immunotherapy response in solid cancers | Roche |
| 8700 | Leo Buckley | Brigham and Women's Hospital | Colchicine Adverse Effects Research in people with Covid-19 randomized to colchicine treatment | Montreal Heart Institute |
| 8712 | Arthur Mikhno | Medtronic Foundation | T1-DEXI Analysis for Exercise Study | Jaeb Center for Health Research Foundation, Inc. |
| 8716 | Ali Cinar | Illinois Institute of Technology | Data Analysis, Classification and Model Development using CGM and Physical Activity Data of people with Type 1 Diabetes | Jaeb Center for Health Research Foundation, Inc. |
| 8720 | George Ntaios | University of Thessaly, larissa, Greece | Association between statin treatment and risk of cardiovascular outcomes and death in patients with atrial fibrillation: an individual patient data meta-analysis | Daiichi Sankyo, Inc., Boehringer Ingelheim |
| 8721 | Jorge Bondia | Universitat Politècnica de València | Modeling of exercise and meal disturbances under free-living conditions for improved performance of single- and dual-hormone artificial pancreas systems | Jaeb Center for Health Research Foundation, Inc. |
| 8722 | Daniele Robesti | IRCCS Ospedale San Raffaele | Assessing the Androgen indifferent prostate cancer patients reponse to novel antiandrogen-based regimen or taxanes. | Johnson & Johnson, Sanofi |
| 8724 | Joel Skaistis | Corewell Health | Effect of Tafamidis on Dementia Medication Initiation: A Post-Hoc Analysis of the ATTR-ACT Trial | Pfizer Inc. |
| 8728, 5987 | Glen Hazlewood | University of Calgary | Disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis incorporating individual patient data | AbbVie, Lilly, UCB, Roche, Pfizer Inc., Johnson & Johnson, Sanofi |
| 8729 | Octavian Adam | Albany Medical College | Time to Initiation of Symptomatic Treatment in untreated Parkinson Disease | Biogen |
| 8747 | Arsalan Shahid | CeADAR: Ireland's Centre for Applied AI at University College Dublin | Unlocking the Secrets of Glucose Variability: A Machine Learning and Data-Driven Analysis of Hypoglycemia and Hyperglycemia | Jaeb Center for Health Research Foundation, Inc. |
| 8750 | Manit Srisurapanont | Chiang Mai University Faculty of Medicine | Depressive Symptoms Responding to Bupropion: A Differential Item Functioning Approach in Patients with Major Depressive Disorder | GlaxoSmithKline |
| 8751 | Diederik Dippel | Erasmus MC University Medical Center | Prediction of the treatment benefit of intravenous alteplase treatment for acute ischemic stroke | Boehringer Ingelheim |
| 8752 | Michelle Condren | University of Oklahoma | Helmsley Charitable Trust RFP | Jaeb Center for Health Research Foundation, Inc. |
| 8753 | Yu-Han Chiu | Harvard T.H. Chan School of Public Health | Dabigatran versus Warfarin in Patients with Atrial Fibrillation: Extending inference from the RE-LY trial to real world target population. | Boehringer Ingelheim |
| 8756 | Eyal Dassau | Eli Lilly and Company | Evaluation of Assessment of insulin utilization in people with type 1 diabetes mellitus using glucose excursions, insulin delivery metrics, and combined with nutrition and exercise information from the T1-DEXI dataset | Jaeb Center for Health Research Foundation, Inc. |
| 8757 | Sandra Tessa Hattenhauer | Medical Clinic III for Hematology, Oncology, Immune-Oncology, Rheumatology, University Hospital Bonn | Baseline immune signature score as predictor for response immunotherapy in HCC | Roche |
| 8758 | Michael Szarek | CPC Clinical Research | Comparison of RGX-202-01 with ramucirumab or aflibercept in the treatment of patients with recurrent colorectal cancer harboring a RAS mutation | Lilly, Sanofi |
| 8760, 4112 | Florian Naudet | CHU Rennes, Clinical Investigation Center INSERM 1414, Department of clinical pharmacology and Adult Psychiatry | Tolerability of duloxetine in the elderly and in younger adults: a systematic review and individual patient data meta-analysis of randomized controlled trials versus placebo. | Lilly, Pfizer Inc., Lundbeck, Takeda, AbbVie |
| 8764 | Giuseppe Cabibbo | University of Palermo | Competing risk factors in survival analyses for advanced hepatocellular carcinoma outcomes. The key role of liver function and impact of drug class | Roche |
| 8765 | Amit Etkin | Alto Neuroscience | Understanding individual differences in response to roflumilast in schizophrenia | AstraZeneca |
| 8766 | Catherine Russon | Exeter Centre of Excellence for Diabetes Research (EXCEED), University of Exeter | Using machine learning methods to predict the risk of exercise-induced hypoglycemia in people with Type 1 diabetes | Jaeb Center for Health Research Foundation, Inc. |
| 8767 | Armando Turchetta | McGill University | Forecasting recruitments in multicenter clinical trials via the time-dependent Poisson-Gamma model | Roche |
| 8768 | Ryan Mizell | Advent Health | Predicting progression in Primary Progressive Multiple Sclerosis with Machine Learning | Roche |
| 8769 | Hyung Seok Park | Yonsei University College of Medicine, Cancer Prevention Center, Yonsei Cancer Center | A novel prediction model of poly ADP ribose polymerase (PARP) inhibitor sensitivity using genomic analyses | Pfizer Inc. |
| 8773, 6118 | Roxana Mehran | The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA | Antithrombotic therapy in patients with atrial fibrillation after percutaneouscoronary intervention: a systematic review and individual patient data network meta-analysis Revision of 6118 | Boehringer Ingelheim, Daiichi Sankyo, Inc., Bristol Myers Squibb |
| 8774 | Paco Welsing | Dept of Rheumatology & Clinical Immunologie, University Medical Center Utrecht | Using the “potential-outcomes framework” to predict added value of more intensive initial therapy for individual early Rheumatoid Arthritis (RA) patients | Roche |
| 8802 | Zhi Xiao | Xiangya Hospital, Central-South University | Roles of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in prognosis in HER2-positive breast cancer with trastuzumab and pertuzumab therapy | Roche |
| 8803 | Temiloluwa Prioleau | Emory University | T1-DEXI Analytics | Jaeb Center for Health Research Foundation, Inc. |
| 8806 | Timothy Gaulton | Mass General Hospital, Harvard Medical School | Obesity and COVID-19 | Lilly, NIAID (a data-sharing platform funded by the National Institutes of Health) |
| 8809 | Jing Yu | Sichuan university | Constructing a predictive model for lung cancer immunotherapy | Tempus AI, Inc. |
| 8815 | Rayid Abdulqawi | King Faisal Specialist Hospital and Research Centre | Effect of Calcium Channel Blocker Therapy in Idiopathic Pulmonary Fibrosis | Roche, Boehringer Ingelheim |
| 8828 | Christopher Moxon | University of Glasgow | Comparison of histophathology in fatal Covid-19 in Malawi with fatal cases in other settings | Hannover Medical School |
| 8833 | Derek Dinart | University of Bordeaux, INSERM U1219 & Institut Bergonié | Optimal estimation of the number of subjects in clinical trials to improve the quality of clinical research and the development of new treatments for cancer patients | Sanofi, Roche, Lilly, Pfizer Inc., Boehringer Ingelheim |
| 8834 | Xiaohua Douglas Zhang | University of Kentucky | Markers derived from continuous glucose monitoring data to guide exercise for T1DM | Jaeb Center for Health Research Foundation, Inc. |
| 8837 | Erin Tallon | Children's Mercy Kansas City | Development of an mHealth-Based Just-In-Time Adaptive Intervention (JITAI) for Promoting Physical Activity in Individuals with Type 1 Diabetes | Jaeb Center for Health Research Foundation, Inc. |
| 8839 | Florencia Tettamanti | AstraZeneca | Predicting survival in chronic lymphocytic leukaemia from measurable residual disease (MRD) kinetics | Roche |
| 8842 | Sheng Luo | Duke University | Clinical and molecular characteristics of hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer: a meta-analysis | Roche, Pfizer Inc., AstraZeneca |
| 8845 | Shenghong Zhang | The first affiliated hospital of Sun Yat-sen University | Biomarkers for predicting long-term outcomes in ulcerative colitis | Takeda, AbbVie, Johnson & Johnson |
| 8846 | Charles Horsburgh | Boston University School of Public Health | Predictors of Emergence of Drug Resistance While on Treatment for MDR-TB: A Meta-Analysis | Otsuka Pharmaceuticals |
| 8848 | Wenrui Hao | Penn State University | Develop a mathematical model for Alzheimer's disease virtual clinical trial | Lilly |
| 8850 | Changsheng Ma | Beijing Anzhen Hospital | The impact of malnutrition on the Efficacy and Safety of empagliflozin for people with heart failure | Boehringer Ingelheim |
| 8853 | Guang Sheng Ling | University of Hong Kong (HKU) Li Ka Shing Faculty of Medicine | Using clinical characteristics of hepatocellular carcinoma (HCC) patients as predictors of their immunotherapy response | Roche |
| 8856 | Fei Ma | Chinese Academy of Medical Sciences and Peking Union Medical College | The impact of human epidermal growth factor receptor 2-low (HER2-low) Expression on the Efficacy of endocrine therapy in Hormone Receptor-positive/HER2-Negative (HR+/HER2-) Breast Cancer | Project Data Sphere, Pfizer Inc., Roche, AstraZeneca, Sanofi |
| 8857 | Zachary Epstein-Peterson | Memorial Sloan Kettering Cancer Center | A phase 2 study of Cerdulatinib in treating Cutaneous T-cell Lymphoma (CTCL). | AstraZeneca |
| 8860 | Yutaka Shimazu | Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy (Ki-CONNECT), Kyoto University Hospital | Pretreatment lymphocyte counts and free light chain ratio predict the efficacy of elotuzumab against relapsed/ refractory multiple myeloma | Bristol Myers Squibb |
| 8864 | Lisa Chow | University of Minnesota | Machine Learning to evaluate glycemic variation with exercise | Jaeb Center for Health Research Foundation, Inc. |
| 8865 | Erin Tallon | Children's Mercy Kansas City | Data driven approaches to inform the development of eating behavior patterns that promote glycemic management in youth with type 1 diabetes | Jaeb Center for Health Research Foundation, Inc. |
| 8873 | Cristina Soguero Ruiz | King Juan Carlos University | Multimodal data-driven analysis of T1D in pediatrics and adults with machine learning | Jaeb Center for Health Research Foundation, Inc. |
| 8874 | Nicola Dalbeth | University of Auckland | An investigation of remission in patients with gout - efficacy of treatments, prediction of remission and outcomes | Takeda |
| 8877 | Cinzia Del Giovane | University Hospital of Modena and Reggio Emilia, Modena, Italy | Antithrombotic therapies for secondary prevention in patients with cryptogenic stroke: a systematic review and network meta-analysis with individual participant data | Boehringer Ingelheim, Sanofi, Daiichi Sankyo, Inc. |
| 8879 | Micaela Morettini | Università Poiltecnica delle Marche | Development of a decision support solution to prevent hypoglycemia during and after exercise in T1D | Jaeb Center for Health Research Foundation, Inc. |
| 8884 | Haotian Zou | Department of Biostatistics and Bioinformatics, Duke University School of Medicine | Risk stratification model for predicting risk of recurrence in human epidermal growth factor receptor 2 (HER2) positive breast cancer patients with pathological complete response after neoadjuvant therapy | Roche |
| 8885 | Giacomo Cappon | University of Padova, Department of Information Engineering (DEI) | ReplayBG-E: Expansion of the ReplayBG software to assess exercise-aware treatments of type 1 diabetes | Jaeb Center for Health Research Foundation, Inc. |
| 8889 | Fabricio Garelli | National University of La Plata and CONICET. | Modelling short and long-term exercise effect on glucose levels from wearable devices’ signal patterns. | Jaeb Center for Health Research Foundation, Inc. |
| 8890 | Konrad Mulrennan | Atlantic Technological University | DEXTER - Diabetes Exercise Training for Enhanced Regulation | Jaeb Center for Health Research Foundation, Inc. |
| 8892 | Eleonora Maria Aiello | University of Trento | Exercise timing and Circadian Rhythms | Jaeb Center for Health Research Foundation, Inc. |
| 8893 | Eleonora Manzoni | University of Padova | Detection and prediction of physical activity in type 1 diabetic subjects | Jaeb Center for Health Research Foundation, Inc. |
| 8896 | Bin Cao | China-Japan Friendship Hospital | Treatment of baloxavir marboxil in immunocompromised patients with influenza infection | Roche |
| 8897 | Rebecca Dean | University of Sussex | The impact of interventions for depression on self-perceptions in young people: A systematic review and meta-analysis | GlaxoSmithKline |
| 8903 | Daniel DeSalvo | Baylor College of Medicine | DeSalvo - BCM Helmsley RFP Improving Exercise With T1D | Jaeb Center for Health Research Foundation, Inc. |
| 8913 | Thomas Hawke | McMaster University | T1-DEXi-T Study: Does exercise training improve the time in range following acute bouts of exercise? | Jaeb Center for Health Research Foundation, Inc. |
| 8921 | Sheng Luo | Duke University | The efficacy of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors in solid tumor patients with different clinicopathological characteristics: a meta-analysis | Daiichi Sankyo, Inc., Roche |
| 8922 | Tomas Koutny | University of West Bohemia | In-Silico modelling | Jaeb Center for Health Research Foundation, Inc. |
| 8924 | Prajakta Belsare | James Madison University | Analyzing exercise settings and the impact of various intensities, durations, and types of exercise on people with Type 1 diabetes. | Jaeb Center for Health Research Foundation, Inc. |
| 8926 | Alessio Cortellini | Department of Surgery and Cancer, Imperial College London, London, UK | The putative differential impact of opioids exposure in patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy or chemotherapy: a post-hoc analysis of the randomized phase 2 POPLAR and phase 3 OAK trials. | Roche |
| 8933 | João Pedro Ferreira | Faculty of Medicine of the University of Porto | Non cardiovascular hospitalizations in heart failure and preserved ejection fraction (HFpEF) and the effect of empagliflozin | Boehringer Ingelheim |
| 8937, 6024 | Cosima Locher | University Hospital Zurich of the University of Zurich, Switzerland | Predictors of placebo response in opioid trials for patients with Chronic Primary Pain – An individual-patient data meta-analysis | Pfizer Inc., AbbVie |
| 8944 | Wesley Kerr | University of Pittsburgh | Evaluation of Time to Event endpoints in randomized controlled trials of multiple antiseizure medications for uncontrolled epilepsy | GlaxoSmithKline, Johnson & Johnson, UCB |
| 8946 | Stuart Pocock | London School of Hygiene and Tropical Medicine | Patterns of heart failure hospitalisations and cardiovascular death in EMPEROR studies | Boehringer Ingelheim |
| 8953 | Wilson Lin | Santa Clara University | Drivers of Algorithm/Technology Use In Type 1 Diabetes Self-Management | Jaeb Center for Health Research Foundation, Inc. |
| 8956 | Sheng Luo | Duke University | A Novel Machine Learning-Based Prediction Model for Outcomes in Patients with previously Untreated Diffuse Large B Cell Lymphoma | Roche, Project Data Sphere |
| 8957 | Dean Bodenham | Imperial College London | Two-sample testing for clinical trials data with missing values | Bayer |
| 8966 | Alberico L. Catapano | IRCCS MultiMedica | Effect of lipid-lowering therapies on lipoprotein(a) levels: a meta-analysis of randomized controlled trials | Sanofi |
| 8985 | Joel Skaistis | Corewell Health | Effect of tafamidis treatment on total cardiovascular and cerebrovascular events in Transthyretin (TTR) cardiac amyloidosis | Pfizer Inc. |
| 8997 | Lewis Carpenter | Arcturis | The integration of clinical trial data, real-world evidence, and novel statistical methods to optimise control arm recruitment in relapsed and refractory multiple myeloma | Sanofi |
| 9004 | Limin Zhao | Nan Chang University | Predicting which breast cancer patients will benefit from Palbiclib treatment through a machine learning model | Pfizer Inc. |
| 9007 | Zhao Xingwang | Jilin University | Prediction of hypoglycemia during and after exercise | Jaeb Center for Health Research Foundation, Inc. |
| 9012 | Barry Greenberg MD | University of California, San Diego | Development of a Machine Learning Based Score to Predict Risk of Sudden Cardiac Death in Patients with Heart Failure with Preserved Ejection Fraction | Boehringer Ingelheim |
| 9016 | Alane Izu | WITS-VIDA | Evaluation of Immune Response of 10-valent Pneumococcal Conjugate Vaccine (PCV-10) in HIV infected and uninfected children | GlaxoSmithKline |
| 9018 | Alessio Cortellini | Department of Surgery and Cancer, Imperial College London (UK) | Differential effect of systemic antibiotics and proton pump inhibitors on clinical outcomes from immunotherapy or placebo as sequential therapy in patients with locally advanced, unresectable non-small cell lung cancer (stage III) who have not progressed following chemoradiation therapy: A post-hoc analysis of the PACIFIC trial. | AstraZeneca |
| 9019 | Philip Johnson | University of Liverpool | Assessing the validity of progression-free survival as an endpoint in clinical trials | Roche, Boehringer Ingelheim, GlaxoSmithKline, Sanofi, AbbVie |
| 9024 | Alain Amstutz | Division Clinical Epidemiology, Department Clinical Research, University Hospital Basel | Effectiveness and safety of janus kinase inhibitors in hospitalized patients with COVID-19: Systematic review and individual patient data meta-analysis of randomized trials | Lilly, IDDO, NIAID (a data-sharing platform funded by the National Institutes of Health) |
| 9053 | Johanna Elin Gehin | Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway | Personalised dosing of certolizumab pegol based on serum concentration in rheumatoid arthritis | UCB |
| 9076 | Alexander Tolmach | MakeSense Digital Health Ltd. | Automatic nutrition assessment based on glucose and insulin data for improvement of carbs counting and investigation of glycemia episodes | Jaeb Center for Health Research Foundation, Inc. |
| 9077 | Anne-Marie Wills | Massachusetts General Hospital | Predictors of Progressive Supranuclear Palsy (PSP) disease progression | AbbVie |
| 9081 | Kyle Greenway | McGill University | Antidepressant effects of bupropion, varenicline, nicotine replacement therapy, and placebo in tobacco users. | Pfizer Inc. |
| 9090 | Lena Friberg | Uppsala University | Dose-exposure-response relationships for ceftazidime-avibactam of value to explore dose individualization strategies | Pfizer Inc. |
| 9093 | Ewan Goligher | Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada | Secondary analysis for estimating heterogeneous treatment effects for the “Drotrecogin Alfa (Activated) in Adults with Septic Shock” trial | Lilly |
| 9098 | Stéphane Oudard | Assitance Publique des Hôpitaux de Paris | External validation of a prognostic score for survival in patients with metastatic castration-resistant prostate cancer (CABASCORE) treated with Cabazitaxel. | Sanofi |
| 9099 | Andrew Sims | Newcastle upon Tyne Hospitals NHS Trust | An exploration of UK real world evidence and comparison with clinical trial data in supporting evaluation of 4 drugs that have exited the United Kingdom’s Cancer Drugs Fund (CDF). | Takeda, Bristol Myers Squibb |
| 9102 | Joel Skaistis | Corewell Health East | Effect of Tafamidis Across the Range of Systolic Function: A Post-Hoc Analysis of the ATTR-ACT Trial | Pfizer Inc. |
| 9103 | JOSE GARCIA-TIRADO | University of Bern | Meal and physical activity behavior in people with type 1 diabetes. A retrospective analysis. | Jaeb Center for Health Research Foundation, Inc. |
| 9104 | Mark Woodward | January AI | January AI T1D | Jaeb Center for Health Research Foundation, Inc. |
| 9105 | Nate Kowahl | Verily Life Sciences | Verily_Analysis | Jaeb Center for Health Research Foundation, Inc. |
| 9106 | Nima Aghaeepour | Stanford University | Identifying Subgroups of Patients with Improved Outcomes in Clinical Trials | Takeda, AbbVie, Daiichi Sankyo, Inc., Lilly, AstraZeneca, Roche, Sanofi, Pfizer Inc., Montreal Heart Institute, Duke University School of Medicine/Duke University Hospital |
| 9121 | Vitalay Fomin | Y-AI inc. | Biomarkers associated with response to monotherapy compared to combination therapy in cancers | Roche |
| 9128 | Pierluigi Navarra | Catholic University Medical School, Rome, Italy | A comparison between the assessments of overall response rate carried out by local assessors and a blinded independent central review in oncology trials. Analysis of differences in the assessment conducted at single-patient level. | Roche |
| 9129 | Yi-Wen Tsai | Institute of Health & Welfare Policy, National Yang Ming Chiao Tung University | Cost-effectiveness analysis of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: subgroups analyses | Roche |
| 9130, 6488 | Feng Sun | School of public health, Peking University | An individual participant data meta-analysis to evaluate new hypoglycemic drugs (SGLT-2i and DPP-4i) on type 2 diabetes mellitus patient sub-groups | Boehringer Ingelheim, Takeda |
| 9132 | Viola Pongratz | Technical University Munich, School of Medicine, Neurology | Monitoring of upper extremity motor function in Multiple Sclerosis (MS): the nine-hole-peg-test in MS revisited | Biogen, Roche, Sanofi |
| 9137 | Ly-Mee Yu | Nuffield Department of Primary Care Health Sciences, University of Oxford | Loop Diuretics and Weight Change in Heart Failure: A Meta-Analysis | Boehringer Ingelheim, Bayer, GlaxoSmithKline |
| 9141 | Shujie Yang | university of Iowa | Fatty Acid Metabolism, Oxidative phosphorylation, and cholesterol homeostasis pathways in endometrial cancer organoids | Tempus AI, Inc. |
| 9228, 8563 | Kenta Yoshida | Genentech/Roche | Tumor Growth Inhibition-Overall Survival (TGI-OS) model development for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer | Pfizer Inc., AstraZeneca |
| 9229 | Andreas Meid | Heidelberg University Hospital, Dept. of Clinical Pharmacology & Pharmacoepidemiology, Im Neuenheimer Feld 410 , 69120 Heidelberg, Germany | MAGIC-BULLET - Model-based support of translational steps throughout drug development of antibody-drug conjugates (ADCs) in breast cancer | Roche, Daiichi Sankyo, Inc. |
| 9230 | Erinne Wasalski | Rutgers University | Health-Related Quality of Life in Breast Cancer Clinical Trials Through the Lens of Race and Ethnicity: The Importance of Understanding the Patient Experience | Pfizer Inc., Roche, Lilly, Boehringer Ingelheim, Daiichi Sankyo, Inc., AstraZeneca |
| 9234 | Matthew Chersich | Wits Reproductive Health Institute at University of the Witwatersrand - Climate and Health Directorate | Developing data science solutions to mitigate the health impacts of climate change in Africa: The Heat and Health African Transdisciplinary Center (HE²AT Center) | Boehringer Ingelheim, Sanofi |
| 9235 | Christian Lood | University of Washington | Neutrophil Lymphocyte Ratio as predictor of treatment response in malignancy | Lilly |
| 9236 | Christian Dansereau | Perceiv AI | Validation of prognostic machine learning tools for forecasting clinical progression to enrich Alzheimer’s disease trials | Lilly, AbbVie, Takeda |
| 9239 | Sheng Luo | Duke University | Impact of Clinical and Molecular Characteristics of Lymphoma Patients on Prognosis and Potential Mechanisms | Roche, GlaxoSmithKline, Takeda |
| 9240 | Michael Kreissl | University Hospital Magdeburg | "Parameters of Body Composition as prognostic biomarkers in patients with RET-altered thyroid cancer treated with selpercatinib" Post-hoc analysis of the LIBRETTO-001 trial | Lilly |
| 9241 | Amit Garg | Department of Dermatology, Northwell Health, New Hyde Park, NY | Association between skin-related quality of life and race in patients with hidradenitis suppurativa, and Repeatability/Intra-rater agreement of lesion counts in hidradenitis suppurativa | AbbVie |
| 9244 | Kazuki Takada | Saiseikai Fukuoka General Hospital, Fukuoka, Japan | Impact of Probiotics on Clinical Outcomes in Patients with Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Atezolizumab Combination Therapy: A Post Hoc Analysis of IMpower133 | Roche |
| 9247 | Giovanni Sebastiani | Italian National Council of Research, Institute for Applied Mathematics "Mauro Picone" | Hypoglicaemic events risk prediction for type 1 diabetes subjects during physical activity | Jaeb Center for Health Research Foundation, Inc. |
| 9250 | Nan Hu | Florida International University | Machine learning augmented decision support system for myocardial revascularization treatment plan selection | Duke University School of Medicine/Duke University Hospital |
| 9252 | Danny Volkaerts | University Colleges Leuven-Limburg, association of Catholic University Leuven, Belgium | Smart Diabetes Assistent | Jaeb Center for Health Research Foundation, Inc. |
| 9253 | Jiajun Yan | McMaster University, Hamilton, Ontario, Canada | Statistical Methods for Analyzing EuroQol 5 Dimension 5 (EQ-5D) in Randomized Clinical Trials | Lilly, Takeda, AbbVie, Biogen, Sanofi, Pfizer Inc. |
| 9274 | Kazuki Takada | Saiseikai Fukuoka General Hospital, Fukuoka, Japan | Prognostic Impact of Probiotic Supplementation on the Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with First-Line Atezolizumab: Pooled Analyses of Five Randomized Control Trials | Roche |
| 9275 | Kazuki Takada | Saiseikai Fukuoka General Hospital, Fukuoka, Japan | Influence of Acetaminophen on Treatment Outcomes in Advanced Non-Small Cell Lung Cancer: Pooled Data Analyses from Five Randomized Control Trials of First-Line Atezolizumab | Roche |
| 9280 | Nuno Filipe de Sousa Vale | Faculty of Medicine, University of Porto | Population Pharmacokinetic Study involving different formulations of Salbutamol | GlaxoSmithKline |
| 9284 | Jiro McKinnis | Virror Health | Associative Analysis of Comorbidities and Clinical Variables with Concomitant Presence of Congestive Heart Failure (CHF) in Patients Undergoing Cardiac Catheterization | Duke University School of Medicine/Duke University Hospital |
| 9285 | Mengyi Lu | Nanjing Medical University | Association of Body Mass Index (BMI) with Prognosis and Safety Profile of Atezolizumab | Roche |
| 9286 | João Sérgio Neves | Faculdade de Medicina da Universidade do Porto | Effect of Exenatide Across the Spectrum of Ejection Fraction: An analysis from the EXSCEL trial | AstraZeneca |
| 9328 | Sebastian Polak | Faculty of Pharmacy, Jagiellonian University Medical College in Poland | Developing a quantitative base for more effective and individualized ropinirole dosing regimen | GlaxoSmithKline |
| 9332 | Neeraj Narula | Hamilton Health Sciences | Outcomes from Induction Using Ustekinumab or Vedolizumab Among Patients Who Have Prior Biologic Intolerance vs Biologic Failure in Ulcerative colitis and Crohn's disease | Johnson & Johnson, Takeda |
| 9350 | Lucy Vivash | Monash University | Evaluation of epilepsy-DOOR (Desirability of outcome ranking) as an outcome measure for therapeutic trials in drug resistant epilepsy | UCB |
| 9352 | Sangwoo Kim | Yonsei University | Conventional genomic predictive markers to immune checkpoint inhibitors are deteriorated in metastatic clear cell renal cell carcinoma | Bristol Myers Squibb |
| 9354 | Li-Xuan Qin | Memorial Sloan Kettering Cancer Center | Tumor Mutational Burden (TMB) Dichotomization for Immunotherapy Outcome Prediction | Tempus AI, Inc. |
| 9360 | Guilherme Polanczyk | University of Sao Paulo (USP) | Moderators of treatment response to stimulants in preschoolers with attention-deficit/hyperactivity disorder: an individual patient data meta-analysis | Takeda |
| 9373 | Amit Etkin | Alto Neuroscience, Inc. | Cognitive factors as predictors of treatment outcomes in patients with Schizophrenia | Boehringer Ingelheim |
| 9377 | Benjamin Haibe-Kains | Princess Margaret Cancer Centre, University Health Network | Biomarker discovery for immunotherapy response via pan-cancer and cancer-specific analyses | Bristol Myers Squibb |
| 9383 | João Pedro Ferreira | Faculty of Medicine of Porto University | Anemia and the Effect of Empagliflozin in HFpEF: findings from EMPEROR-Preserved | Boehringer Ingelheim |
| 9384 | Evyn Peters | University Of Saskatchewan | Episode duration and severity as predictors of response to desvenlafaxine and placebo in patients with major depressive disorder | Pfizer Inc. |
| 9388 | Ritu Lal | GEn1E Lifesciences Inc. | A Prospective Machine Learning Model for the Identification of Sepsis Endotypes | Lilly |
| 9389 | Sinbad Xia | The Clinical Research Center for Respiratory Diseases of Zhejiang Province, Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine | Predictors of survival in patients with extensive-stage small-cell lung cancer | Roche |
| 9390 | Joseph Merola | The International Dermatology Outcome Measures Group (IDEOM) | Musculoskeletal Symptoms in Hidradenitis Suppurativa | AbbVie |
| 9399 | Philip Johnson | University of Liverpool | A novel, evidence-based approach to clinical trial design in patients with advanced liver cancer (hepatocellular carcinoma); single arm studies with a virtual control group | Roche, Boehringer Ingelheim, Bayer, Sanofi, GlaxoSmithKline |
| 9407 | Josep Vehi | University of Girona | Validation of new exercse models and therapy optimization | Jaeb Center for Health Research Foundation, Inc. |
| 9410 | Abhinav Sharma | The Research Institute of the McGill University Health Centre | Proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibitors on Cardiovascular and Heart Failure Outcomes | Pfizer Inc. |
| 9417 | Vipul Jairath | Alimentiv Inc. | Determining Endoscopic Treatment Response in Ulcerative Colitis and Crohn’s Disease using the Win Probability Approach | Johnson & Johnson, AbbVie, Takeda, Pfizer Inc. |
| 9422 | James Salsbury | University of Sheffield | Developing methodology for a delayed treatment effect present in a survival trial | Roche, Bristol Myers Squibb |
| 9433 | Yang Li | School of Statistics, Renmin University of China | A new Statistical method to balance Social Network Effect and Covariate Effect in Response Adaptive Design | GlaxoSmithKline |
| 9434 | Victor Moreno | Victor Moreno, Director of START Madrid-Fundacion Jimenez Diaz (FJD) | Retrospective analysis of different doses of atezolizumab in patients with advanced solid tumors | Roche |
| 9462 | Chandra Kanth Nagesh | University of Colorado Boulder | Analysis-of-Type-1-Diabetes | Jaeb Center for Health Research Foundation, Inc. |
| 9470 | Joseph Cafazzo | Toronto General Hospitable Research Institute, University Health Network | Can we trust GPT-4 Turbo Vision to estimate carbohydrate and caloric content from food images within the broad context of diabetes? | Jaeb Center for Health Research Foundation, Inc. |
| 9474 | Daniel Adam Blanco | Inari Medical, Inc. | Comparative Analysis of Health-Related Quality of Life in Pulmonary Embolism Survivors: PEmb-QoL versus EQ-5D Instruments | Daiichi Sankyo, Inc. |
| 9478 | Lena Friberg | Uppsala University | Study on impact of scanning intervals of follow up tumor assessments on Progression Free Survival (PFS) and median PFS for Non-Small Cell Lung Cancer (NSCLC) patients treated with Atezolizumab and Docetaxel. | Roche |
| 9480, 6629 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers and patient reported outcomes(PROs) as dynamic predictors to identify efficacy and safety of non–small-cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) | Roche, AstraZeneca, Lilly |
| 9481 | Nathalie Germain | Universite Laval | Melatonin and melatonin receptor agonists for the treatment of sleep disturbances associated with neurocognitive disorders. | Takeda |
| 9492, 8697 | David McAllister | University of Glasgow | Understanding frailty, multimorbidity and renal failure in clinical trials: Attrition, retention and heterogeneity of treatment effects in trials for diabetes, cancer and a heterogenous set of index conditions | Takeda, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Lilly, GlaxoSmithKline, Roche, UCB, Sanofi |
| 9731, 7826 | Carl Turesson | Lund University | Efficacy and safety of TNF inhibitors in seronegative rheumatoid arthritis (update) | Johnson & Johnson, Lilly, AbbVie, UCB, Pfizer Inc., Roche |
| 9734 | James Brorson | The University of Chicago | Merging data from acute stroke secondary prevention trials for analysis of stroke recurrence risks | AstraZeneca |
| 9735 | Edouard Auclin | Institut Bergonié | Prognostic and predictive value of the lung immune prognostic index in patients with advanced small cell lung cancers treated with immune checkpoint inhibitors | AstraZeneca, Roche |
| 9736 | Stefan Leucht | Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, School of Medicine and Health, Technical University of Munich | Sex differences in antipsychotic side-effects and efficacy in adults with acute exacerbations ofschizophrenia: an individual-participant network meta-analysis | Lilly, Servier , Johnson & Johnson, GlaxoSmithKline, AbbVie |
| 9738 | Onyekachukwu Illoh | University of Maryland, Baltimore | Translating Causal Inferences from Randomized & Single-Arm Trials to Externally-Controlled Trials | Boehringer Ingelheim |
| 9739 | David Auerbach | SUNY Upstate Medical University | Assessment of cardiac electrical function and prevalence of electrocardiographic abnormalities in patients diagnosed with Dravet Syndrome and Lennox-Gastaut Syndrome | UCB |
| 9746 | María Elena Hernando Pérez | Universidad Politécnica de Madrid | PROPHECY: Preprandial Optimized Glucose Prediction with Objective Physical Exercise andCarbohydrate Estimation for Insulin Calculation in Do-it-Yourself Systems | Jaeb Center for Health Research Foundation, Inc. |
| 9748 | Ho So | Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong | Causal inference in retrospective rheumatoid arthritis clinical studies | Roche, AbbVie |
| 9764 | Wenjun Yi | the Second Xiangya Hospital of Central South University | Assessing the Efficacy of Trastuzumab Emtansine (T-DM1) in Human Epidermal Growth Factor Receptor 2 (HER2)+ Breast Cancer Across Varying Hormone Receptor Statuses | Roche |
| 9767 | Rohan Khera | Yale School of Medicine | A computational phenomapping approach to personalize the cardiometabolic benefits of novel glucagon-like peptide-1 receptor and glucose-dependent insulinotropic polypeptide agonists in patients with type 2 diabetes mellitus | Lilly |
| 9770 | Massimo Gentile | Hematology Unit of AO Cosenza | Comparison between Eloquent-3 data with real-life data | Bristol Myers Squibb |
| 9771 | Li Yang | Renmin University of China | Covariate selection and adaptive randomization for sequential experiments | Boehringer Ingelheim |
| 9774 | Aristeidis Katsanos | Population Health Research Institute, Hamilton Health Sciences Corporation | Individual Participant Data Meta-Analysis of Randomized Trials of Anticoagulation compared to Antiplatelet Therapy in Patients with Embolic Strokes of Undetermined Source | Boehringer Ingelheim |
| 9783 | Kihyuk Shin | Pusan National University Yangsan Hospital | Age-Stratified Analysis of Acne as an Adverse Event in Patients Treated with Janus Kinase Inhibitors: A Systematic Review and Meta-Analysis | AbbVie, Pfizer Inc. |
| 9787 | Hongmei Zheng | Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology | Clinical and molecular characteristics of human epidermal growth factor receptor 2-positive breast cancers: a meta-analysis | Roche |
| 9792 | maria pia sormani | University of Genoa | Defining responders to teriflunomide treatment in Multiple Sclerosis | Sanofi |
| 9793 | Lea Dousset | Translational Research Institute, The University of Queensland, Brisbane, Australia | Immunotherapy as Prophylaxis: Exploring the Potential Impact on Hyper-Chronic Non-Melanoma Skin Cancers in Retrospective Melanoma Cohorts | Bristol Myers Squibb |
| 9797 | Dr Julian Stiels | OneTwenty AG | Advanced blood glucose prediction modelling | Jaeb Center for Health Research Foundation, Inc. |
| 9809 | Emma Fröling | Universitätsmedizin Charité Berlin, clincic for psychiatry and psychotherapy | Systematic Review and Meta-Analysis of Adverse Events During Levetiracetam Therapy | UCB |
| 9811, 10462 | Derek Chu | McMaster University | Efficacy and safety of monoclonal antibodies in patients with uncontrolled asthma: a systematic review and network meta-analysis. | Roche, GlaxoSmithKline, ImmPort (a data-sharing platform funded by the National Institutes of Health), Johnson & Johnson |
| 9813 | Sameer Jauhar | King's College London, Centre for Affective Disorders | Conducting a systematic review and meta-analysis to assess the incidence and severity of withdrawal symptoms following discontinuation of antidepressants | Lundbeck, Takeda, Pfizer Inc., Lilly |
| 9815 | Tim Greten | Center for Cancer Research, National Cancer Institute, NIH | Locoregional therapy impact on immunotherapy | Roche |
| 9817 | Marco Gerlinger | Barts Cancer Institute, Queen Mary University of London | To determine whether Programmed Cell Death Ligand 1 (PDL1) expression in oesophago-gastric cancer differs depending on the tumour site from which the biopsy was taken from. | Bristol Myers Squibb |
| 9821 | Richard Franzese | GSK | Assessment of the predictive value of longitudinal circulating tumour deoxyribonucleic acid (ctDNA) dynamics for survival outcomes in non-small-cell lung cancer (NSCLC) | Roche |
| 9822 | Shuhua Yi | Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College | Clinical and molecular characteristics of Non-Hodgkin Lymphoma | Roche, Takeda |
| 9824 | Martin Okun | Fort HealthCare | Using Patient-Level Data from Psoriasis Clinical Trials to Evaluate the Quantitative Relationship between Changes in Skin and Nail Psoriasis | Lilly |
| 9826 | Lorna Wheaton | University of Leicester | Development and application of new statistical methods for meta-analysis to evaluate treatment effectiveness and surrogate relationships in biomarker subgroups | AstraZeneca, Roche |
| 9829 | Yuanyuan Kong | Beijing Friendship Hospital, Capital Medical University; Methodological Platform at the National Clinical Research Center for Digestive Diseases | Clinical and molecular profiles of Hepatocellular Carcinoma (HCC) treated with combination immunotherapy | Roche |
| 9834 | Tao Han | The First Hospital of China Medical University | Clinical and molecular profiles of Hepatocellular Carcinoma (HCC) | Bayer, Roche, Sanofi, Boehringer Ingelheim, NIDDK Central |
| 9835 | Yuya Matsue | Juntendo University School of Medicine Graduate School of Medicine | Impact of serum hepcidin levels on the efficacy of daprodustat treatment in patients with chronic kidney disease | GlaxoSmithKline |
| 9841 | Anke Richters | The Netherlands Comprehensive Cancer Organisation | Estimating heterogeneous treatment effects of immunotherapy combination regimens for treatment of advanced/metastatic clear cell renal cell carcinoma: an individual patient data meta-analysis | Bristol Myers Squibb |
| 9845 | Yao Zhu | Fudan University Shanghai Cancer Center | Serum sodium maintenance levels and outcomes in patients with advanced prostate cancer | Bayer, Sanofi |
| 9846 | Samantha Kleinberg | Stevens Institute of Technology | Examining Effects of Meals on Glucose in Individuals with Type 1 Diabetes | Jaeb Center for Health Research Foundation, Inc. |
| 9848 | Garrett Ash | Yale School of Medicine | Developing a pre-trainable foundation time series model for blood glucose prediction among people with type 1 diabetes (T1D) and then applying it to a vulnerable, understudied subset of them | Jaeb Center for Health Research Foundation, Inc. |
| 9863 | Yasuhiro Hagiwara | The University of Tokyo | Development of Covariate Adjustment Methods to Improve Efficiency of Randomized Clinical Trials for human immunodeficiency virus infected Patients | GlaxoSmithKline |
| 9866 | Weituo Zhang | Shanghai Jiao Tong University School of Medicine | comparing the methods of selecting and adjusting for covariates in clinical study | Lilly |
| 9870 | Alexandre Betourne | Critical Path Insitute | Integration of Biogen Choroideremia Data (NCT03359551 ; NTCNCT03496012) into the Rare Diseases Cures Accelerator Data and Analytics Platform (RDCA-DAP) | Biogen |
| 9890 | Jasmine Mitchell | University of California, Los Angeles | The Effect of Serotonin Reuptake Inhibitors in Metastatic Colorectal Cancer | Roche |
| 9906 | Alessio Cortellini | Department of Surgery and Cancer Imperial College London, London | The putative role of Proton-Pump Inhibitors in patients with Basal Cell Carcinoma treated with vismodegib | Roche |
| 9907 | Akihiro Hirakawa | Tokyo Medical and Dental University | Developing new statistical methodology harnessing nonconcurrent control data in infectious disease platform trials | Montreal Heart Institute, Lilly, NIAID (a data-sharing platform funded by the National Institutes of Health) |
| 9908 | Haitao Zhao | Peking Union Medical College Hospital | The clinical and prognostic features of acquired resistance to immune-checkpoint inhibitors (ICIs) in Hepatocellular carcinoma (HCC) | Roche |
| 9909 | John Clemmer | University of Mississippi Medical Center | Improving heart failure with preserved ejection fraction (HFpEF) treatment using a mathematical model of physiology | Boehringer Ingelheim |
| 9910 | Yang Li | Renmin University of China | Missing data considerations for patient reported outcome measures in randomized controlled trials | Pfizer Inc. |
| 9911 | Kazuki Takada | Saiseikai Fukuoka General Hospital, Fukuoka, Japan | Prognosis of inoperable patients after preoperative atezolizumab administration: A post hoc analysis of Lung Cancer Mutation Consortium (LCMC) 3 | Roche |
| 9920 | Soumyajit Roy | University Hospitals Cleveland Medical Center | Does Timing of Metastatic Presentation (Synchronous versus Asynchronous) Affect Outcome in Advanced Urothelial Carcinoma? | Roche, Lilly, AstraZeneca |
| 9924 | Thomas Büttner | Department of Urology and Pediatric Urology, University Hospital Bonn | Evaluation of Bellmunt Risk Score as a prognostic score in metastatic-castration resistant prostate cancer | Johnson & Johnson, Takeda, Sanofi |
| 9939 | Xiaoyu Yan | The Chinese University of Hong Kong | Organ specific tumor dynamic predict survival in patients with metastatic breast cancer | Roche, Pfizer Inc., Lilly |
| 9960 | Zhengfei Zhu | Fudan University Shanghai Cancer Center | Organ-specific response to atezolizumab and radiotherapy in advanced non-small cell lung cancer patients: a pooled analysis | Roche |
| 9962 | Yukinori Ozaki | The Cancer Institute Hospital of Japanese Foundation for Cancer Research | Exploring risk factors and prognosis in cancer patients receiving immune checkpoint inhibitor therapy with immune-related adverse events | Roche, AstraZeneca, Daiichi Sankyo, Inc., GlaxoSmithKline, Project Data Sphere, ONO |
| 9963 | Hanna Suominen | The Australian National University | Develop Type 1 Diabetes Simulators/Models for Exercise in Type 1 Diabetes. | Jaeb Center for Health Research Foundation, Inc. |
| 9964 | João Sérgio Neves | Faculdade de Medicina da Universidade do Porto | Effects of tirzepatide versus semaglutide on cardiovascular risk in patients with type 2 diabetes | Lilly |
| 9966 | Luis Farhat | University of São Paulo (USP) | An evaluation of lack of early improvement and later non-response in early-onset schizophrenia: a systematic review and meta-analysis of randomized controlled trials. | Johnson & Johnson, Lilly, Otsuka Pharmaceuticals |
| 10028 | Hanne Vanluchene | AZ Delta | Development of an Inflammatory Bowel Disease (IBD) patient population dashboard to monitor and improve care through machine learning | Johnson & Johnson, AbbVie |
| 10030 | Lihi Eder | Women's College Hospital and University of Toronto | Exploring Sex-related Mechanisms of Psoriatic Arthritis (PsA) response to advanced therapies (EXSEMP): Individual participant data (IPD) meta-analysis of randomized controlled trials of advanced therapies | AbbVie, Johnson & Johnson, Lilly, Pfizer Inc. |
| 10032 | Shenghong Zhang | The first affiliated hospital of Sun Yat-sen University | Dynamics of Disease Activity in Monitoring Therapeutic Outcomes and Predicting Prognosis for Ulcerative Colitis | Johnson & Johnson, Takeda |
| 10036 | Akihiro Hirakawa | Tokyo Medical and Dental University | Development of statistical methodology considering placebo response in randomized controlled trials targeting Alzheimer's disease | Lilly |
| 10037 | Shenghong Zhang | The first affiliated hospital of Sun Yat-sen University | Dynamics of Disease Activity in Monitoring Therapeutic Outcomes and Predicting Prognosis for Crohn's disease | Takeda, Johnson & Johnson, AbbVie |
| 10039, 8807 | Lena Friberg | Uppsala University | Evaluation of dose individualization strategies in optimizing survival and patient-reported outcomes of sunitinib treatment in patients with metastatic renal cell carcinoma | Pfizer Inc. |
| 10046 | Matthew Galsky | Icahn School of Medicine at Mount Sinai | Exploring C-reactive protein (CRP) dynamics and resistance to immunotherapy in bladder cancer | Roche |
| 10047 | Ramona Belfiore-Oshan | Critical Path Institute | Bayesian item response theory model for the North Star Ambulatory Assessment (NSAA) rating scale | Cure Duchenne |
| 10049 | Dag Aarsland | King's College London | Neutrophil to Lymphocyte Ratio Decrease and Its Association with Clinical Changes in Late-Life Depression Treated with Vortioxetine (Lu AA21004) | Lundbeck |
| 10052 | Yasuhiro Hagiwara | The University of Tokyo | Adjusting for treatment switching in Oncology Trials: Sensitivity Analysis for Rank-Preserving Structural Failure Time Model | Roche, Pfizer Inc. |
| 10054 | Lisa Koch | University of Bern Clinic for Diabetology, Endocrinology, Nutritional Medicine and Metabolism | Foundational machine learning models for large scale robust modelling of continuous glucose monitoring and activity data | Jaeb Center for Health Research Foundation, Inc. |
| 10055 | Christian Torp-Peteresen | North Zealand Hospital | Reanalyzing Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPAREG) using Longitudinal Targeted Maximum Likelihood Estimation (LTMLE) analysis. | Boehringer Ingelheim |
| 10090 | David Baker | Queen Mary University of London | Monitoring white blood cells as an indicator to assess the risks of treatment failure in multiple sclerosis | Biogen |
| 10091 | Jonas Saal | University Hospital Bonn | Establishing a risk score for Skeletal Related Events (SRE) in patients with cancer | Project Data Sphere, Bayer, Johnson & Johnson, Sanofi |
| 10094 | Sabatina Criscuolo | University of Naples Federico II | Machine Learning approach for glycemia prediction in type 1 diabetes | Jaeb Center for Health Research Foundation, Inc. |
| 10095 | Michael Greicius | Stanford University | Repurposing clinical trial data to understand potential effects of functional unblinding on efficacy of Alzheimer's drug - Gantenerumab | Roche |
| 10098 | Yohei Sekino | Department of Urology at Hiroshima University | The potential prognostic value of body mass index in patients with urothelial carcinoma and renal cell carcinoma treated with immunotherapy and tyrosine kinase inhibitor. | Roche |
| 10106 | mehmet fatih özbay | Kirsehir Training and Research Hospital | Exploring the Correlation between Programmed Death-Ligand 1 (PD-L1) Levels and Eosinophilia in Advanced Lung Cancer Patients Treated with Atezolizumab | Roche |
| 10112 | Alessio Cortellini | Imperial College London | TP53 missense and truncating mutations may be linked to differential response to checkpoint blockade in patients with advanced non-small cell lung cancer: a post hoc analysis of the OAK and POPLAR trials. | Roche |
| 10116 | Jean-Pierre Fauvel | Hospices Civils de Lyon, University Claude Bernard Lyon 1 | Development and validation of clinical prediction tools to estimate all-cause mortality, cardiovascular and renal risk in non-dialysis chronic kidney disease (CKD) patients using machine learning | GlaxoSmithKline |
| 10118 | Neeraj Narula | Hamilton Health Sciences | Assessing Outcomes from the EXTEND Clinical Trial Using the Modified Multiplier of the Simple Endoscopic Score for Crohn's disease (MM-SES-CD) | AbbVie |
| 10120 | Pablo Bonangelino | US Food and Drug Administration | A Bayesian borrowing-by-parts method integrated with propensity score stratification for borrowing adult data for pediatric patients | GlaxoSmithKline |
| 10121 | Itsuki Osawa | Columbia University Irving Medical Center | Optimized timing of empagliflozin use for cardiorenal protection: a post-hoc analysis of the EMPA-REG OUTCOME, EMPEROR-REDUCED, and EMPEROR-PRESERVED clinical trials | Boehringer Ingelheim |
| 10126 | Wataru Fukuokaya | The Jikei University School of Medicine | Heterogeneous treatment effects of cabazitaxel in patients with castration-resistant prostate cancer | Sanofi |
| 10137, 9844 | Mariam Khayretdinova | Brainify.AI | Predicting Placebo Response in Major Depressive Disorder on Clinical Trials Data Using Artificial Intelligence (AI)/Machine Learning (ML) on Clinical Data | Takeda, Lilly, Lundbeck, Pfizer Inc., Johnson & Johnson |
| 10138 | Issa Dahabreh | Harvard T. H. Chan School of Public Health | Development of statistical methods for comparison of the efficacy of anticoagulants in non-valvular atrial fibrillation | Daiichi Sankyo, Inc., Boehringer Ingelheim |
| 10146 | Yuki Miyai | Nagoya University Hospital | Impact of Body Mass Index on Survival and Response in Cancer Patients Treated with Immune Checkpoint Inhibitors | Project Data Sphere, ONO, Roche, AstraZeneca |
| 10151 | Anthony Willems | University Ghent | The Impact of Sex, Age and Race on the Immunogenicity of Meningococcal Serogroup B Vaccination in Healthy Infants, Children, Adolescents and Young Adults: A Systematic Review and Meta-Analysis | Pfizer Inc. |
| 10155 | Brian Gillette | Droice Labs | Developing approaches to accelerate clinical trials using real world data (RWD) from electronic health records (EHR) | Lilly, Takeda, Daiichi Sankyo, Inc. |
| 10158 | Si-Cong Ma | The First Affiliated Hospital of Sun Yat-Sen University | Biomarker-based strategies to enhance efficacy and reduce toxicity in lung cancer immunotherapy | Roche |
| 10200 | Dafne Capelusnik | Care and Public Health Research Institute (CAPHRI), Maastricht University | Assessment of peripheral arthritis and related disease activity measurement instruments in spondyloarthritis | Lilly, UCB, Johnson & Johnson, Pfizer Inc., AbbVie |
| 10204 | Yanguang Cao | University of North Carolina at Chapel Hill | Identifying Prognostic and Predictive Factors for Causal Exposure-Response Analysis of Imatinib in Treatment of Chronic Myeloid Leukemia | Pfizer Inc., Takeda |
| 10273 | Andrea Wiencierz | Department of Clinical Research, University of Basel, University Hospital | TransPALLAS study request_Vetter_209-C | Alliance Foundation Trials, LLC (AFT) |
| 10279 | Laetitia de Abreu Nunes | Pragmatic Clinical Trials Units, Queen Mary University of London | Examining statistical methods that leverage the hierarchical structure of adverse events for signal detection in randomised controlled trials | Pfizer Inc., Biogen |
| 10290 | Jeffrey Bower | Sana Health, INC. | Anchor Based Minimal Clinical Important Difference calculation for the Neuropathic Pain Inventory Scale | Pfizer Inc. |
| 10291 | Chanho Lee | Yonsei University College of Medicine | Effects of ezetimibe on clinical outcomes in patient with idiopathic pulmonary fibrosis (IPF) | Boehringer Ingelheim |
| 10293 | Joao Pedro FERREIRA | Faculty of Medicine of Porto University | Effect of Empagliflozin on Blood Pressure in Acute Heart Failure | Boehringer Ingelheim |
| 10313 | linsen ye | The Third Affiliated Hospital,Sun Yat-Sen University | Effect of liver lipid deposition on the treatment of atezolizumab plus bevacizumab: a retrospective study based on the IMBrave150 | Roche |
| 10317 | Kelley Kidwell | University of Michigan School of Public Health | Seamless Design for Multiple Endpoints for Drug Development in Rare Diseases Using Gaussian Copula Model in Bayesian Framework : a case study from Hunter syndrome | Takeda |
| 10332 | Raphaèle Seror | Immunology of Viral Infections and Autoimmune Diseases, INSERM | Retrospective validation of the Sjögren's Tool for Assessing Response (STAR) as a primary endpoint for response to treatment in Primary Sjögren's Syndrome | Servier |
| 10360 | Javier Calvo | Universidad de Costa Rica | Identifying Clinical Predictors of Weight Loss in Older Adults with Diabetes: Insights from SURPASS Clinical Trials | Lilly |
| 10381 | Neeraj Narula | Hamilton Health Sciences | Impact of Concomitant Steroid Use on Adverse Events in Ulcerative Colitis Clinical Trials | Johnson & Johnson, AbbVie, Takeda, Pfizer Inc. |
| 10390 | Aaron Mansfield | Mayo Clinic | Comparison of the transcriptomic profiles of small cell lung cancer (SCLC) patients who are younger or have never smoked | AstraZeneca |
| 10391 | You-Shan Feng | Universitätsklinikum Tübingen | Psychometric properties and scoring approaches for the EuroQol-5 dimension-5 level (EQ-5D-5L) Psoriasis-specific questions | Lilly |
| 10403 | Andreas Meid | Heidelberg University Hospital | TREND-RIVIVAL - Trial results extension and disease course modelling for real-world evidence and valid inferences in the post-approval phase | Project Data Sphere, Takeda |
| 10404 | Marco Sanduzzi Zamparelli | BCLC group, Liver Unit. Hospital Clinic of Barcelona | Effect of PPIs (proton-pump inhibitors) on treatment efficacy in patients with hepatocellular carcinoma | Roche |
| 10406 | Toby Pillinger | King's College London (UK) | Physiological effects of acute antidepressant treatment in psychiatric disorders: a systematic review and network meta-analysis | Takeda, Lundbeck, Lilly, GlaxoSmithKline, Pfizer Inc. |
| 10408 | Su Syonmez | Orchard Therapeutics 245 Hammersmith Road, 3rd Floor London W6 8PW United Kingdom | Natural History Study of Patients With Mucopolysaccharidosis type IIIA (MPS IIIA) | Takeda |
| 10411 | João Pedro Ferreira | Faculty of Medicine of Porto University, Porto, Portugal | NSAIDs use and kidney outcomes in Heart Failure | Boehringer Ingelheim |
| 10441 | Amber Salter | UT Southwestern Medical Center | Examining Heterogeneity in Response to Disease-Modifying Therapy in Multiple Sclerosis | Roche, Sanofi, Biogen |
| 10443 | Vitalay Fomin | YAI INC. | 2024 DataWorks! Prize: Analyzing COVID-19 Drug Approval and Patient Response Using Historical Data | Montreal Heart Institute, Salix Pharmaceuticals, HCor Research Institute, Certara, Hannover Medical School, Vaccines & Infectious Diseases Analytics Research Unit, Wits Health Consortium, Hospital Universitario Australia, The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, University of Washington, University of Minnesota, Johns Hopkins University |
| 10450 | Sam Royston | Replica Health | Merging Big Datasets for Training Blood Glucose Prediction Models | Jaeb Center for Health Research Foundation, Inc. |
| 10462 | Nermin Diab | McMaster University | Efficacy and safety of monoclonal antibodies in patients with uncontrolled asthma: a systematic review and network meta-analysis (2) | GlaxoSmithKline, Johnson & Johnson, ImmPort (a data-sharing platform funded by the National Institutes of Health) |
| 10463 | Chee Lee | The University of Sydney | Meta-analysis of chemoimmunotherapy for epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) | Bristol Myers Squibb |
| 10464 | Maria Panagiotou | University of Bern | Blood Glucose Prediction | Jaeb Center for Health Research Foundation, Inc. |
| 10466 | Mia Jovanova | University of St. Gallen - School of Medicine | Temporal dynamics of lifestyle factors and glycemic control among children with Type-1 Diabetes | Jaeb Center for Health Research Foundation, Inc. |
| 10467 | Lewis Carpenter | Arcturis | Measurement Error in Real-World Comparative Effectiveness Studies of Progression Free Survival in Multiple Myeloma | Bristol Myers Squibb |
| 10469 | Shenghong Zhang | The first affiliated hospital of Sun Yat-sen University | Predictors and prediction model for therapeutic outcomes in UC patients receiving Mirikizumab | Lilly |
| 10471 | Khandan Keyomarsi | The University of Texas MD Anderson Cancer Center | Validation of Predictive Molecular Biomarker for Predicting Response to Cyclin-Dependent Kinase 4 and 6 (CDK4/6) Inhibitors in Breast Cancer Using Data from PALOMA-2 and PALOMA-3 Studies | Pfizer Inc. |
| 10475 | jiabin cai | associate chief physician，Department of Liver Surgery and Transplantation of Zhongshan Hospital, Shanghai China | Clinical and Molecular Characterization of Advanced Hepatocellular Carcinoma: Analysis of Therapeutic Responses Across Multiple Treatment Regimens | Project Data Sphere, ImmPort (a data-sharing platform funded by the National Institutes of Health), Bayer, Sanofi |
| 10486 | DongKeon Yon | Center for Digital Health, Medical Science Research Institute, Kyung Hee University | Validation of Abrocitinib's efficacy and safety in moderate-to-severe atopic dermatitis across racial, ethnic, and skin type subgroups using machine learning models | Pfizer Inc. |
| 10487 | Surya Bhatt | RespirAnalytics LLC | Response to placebo in patients with chronic obstructive pulmonary disease | Boehringer Ingelheim, AstraZeneca |
| 10491 | Jaeyoun Choi | UC San Diego | The effect of frailty and old age on the efficacy and safety of biologics and small molecules in inflammatory bowel disease : A pooled analysis of individual patient data | Takeda, AbbVie, Johnson & Johnson, Pfizer Inc., Lilly |
| 10492 | Yongwen Zhou | The third affiliated hospital of SYSU | Reinforcement learning in automated insulin delivery | Jaeb Center for Health Research Foundation, Inc. |
| 10495 | Jonas Saal | University Hospital Bonn | Investigation of the impact of serum electrolytes on the efficacy of immune-checkpoint blockade for solid cancer | AstraZeneca, Roche, Lilly |
| 10499 | Stefan Koudstaal | Erasmus Medical Center Rotterdam, NL | Personalized Lifetime Prediction of Survival and Treatment Benefit in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: the LIFE-Preserved Model | Boehringer Ingelheim |
| 10511 | Min Hyuk Lim | UNIST (Ulsan National Institute of Science and Technology) | A study of establishing Machine Learning (ML) and Artificial Intelligence (AI) models for glucose dynamics. | Jaeb Center for Health Research Foundation, Inc. |
| 10540 | Alexander Drilon | Memorial Sloan Kettering Cancer Center (MSKCC) | Do patients with lung cancers positive for a RET gene alteration benefit from the addition of immunotherapy to chemotherapy? | Lilly |
| 10549 | Sumayyah Patel | University of Leeds | Cognition in Myeloma: A Systematic Review and Meta-analysis | Takeda |
| 10703 | Hong Jae Chon | CHA Bundang Medical Center | A validation study of a machine learning model for predicting clinical benefit in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab. | Roche |
| 10706 | Neeraj Narula | Hamilton Health Sciences | Assessing the Impact of Disease Duration on the Likelihood of Healing in the Ileum and Colon in Crohn’s Disease | AbbVie, Takeda, Johnson & Johnson |
| 10707 | Zisheng Chen | The Affiliated Qingyuan Hospital (Qingyuan People's Hospital) of Guangzhou Medical University | The Association between Liver Metastasis of Non-Small Cell Lung Cancer and Prognosis Based on Immunotherapy: A Secondary Summary analysis of Individual Patient Data from Randomized Trials | Roche, AstraZeneca |
| 10730 | David Byrne | RCSI University of Medicine and Health Sciences | Can network analysis be used to inform better treatment plans in anxiety and depression randomised trials? Assessing underlying assumptions and predicting treatment efficacy. | Pfizer Inc., GlaxoSmithKline, Lundbeck, Lilly, Takeda |
| 10732 | Bryan Saunders | University of Sao Paulo | Semaglutide for weight loss: Where is the weight loss coming from? A systematic review and meta-analysis | Lilly |
| 10735 | Andrew Achaiah | Gloucestershire Royal Hospital, Gloucestershire Hospitals NHS Foundation Trust | Exploration of change in forced expiratory volume:forced vital capacity (FEV1:FVC) ratio from baseline to prognosticate clinical outcomes in idiopathic pulmonary fibrosis and predict treatment response to Nintedanib | Boehringer Ingelheim |
| 10740 | Thomas Schnitzer | Northwestern University Feinberg School of Medicine | Predictors of Pain Response in Knee OA | Lilly, Pfizer Inc., Regeneron |
| 10749 | Dennis Shung | Yale School of Medicine | DT1D: Digital Twin for Type 1 Diabetes | Jaeb Center for Health Research Foundation, Inc. |
| 10752 | Anna Maria Claudia Wägner | Fundacion canaria Institudo de investigación sanitaria de Canarias (FCIISC) | Exercise in Type 1 Diabetes | Jaeb Center for Health Research Foundation, Inc. |
| 10757 | Zhaojin Chen | Saw Swee Hock School of Public Health, National University of Singapore | Analyzing the Effectiveness of a New Cancer Treatment Using Historical Data in a Phase II Clinical Trial | AstraZeneca |
| 10783 | Kathryn Connelly | Monash University School of Clinical Sciences | Can a core set of disease activity domains define response in systemic lupus erythematosus clinical trials? An analysis of two Phase 3 randomised controlled trials of belimumab | GlaxoSmithKline |
| 10785 | Jin Woo Choi | Seoul National University Hospital | Evaluating the Efficacy and Safety of Systemic Treatments with Atezolizumab Plus Bevacizumab or Sorafenib in Patients with Hepatocellular Carcinoma and Localized Portal Vein Tumor Thrombosis | Roche |
| 10786 | Yuan Huang | Yale University | Jointly modeling hypoglycemic event times and longitudinal glucose measurement with Brownian motion | Jaeb Center for Health Research Foundation, Inc. |
| 10816 | Shunan Qi | Senior doctor, Cancer Hospital Chinese Academy of Medical Sciences | Analysis of Clinical Molecular Consistency and Treatment Benefit in lymphoma | Sanofi, Takeda, Project Data Sphere |
| 10827 | Ben Cowling | The University of Hong Kong | Exploring Viral Shedding, Symptom Dynamics, and Antiviral Efficacy in Influenza Transmission | Roche |
| 10829 | Hollie Pilkington | Lumanity | Comparison of statistical methodologies for comparing metastatic renal cell carcinoma treatments | Pfizer Inc., Project Data Sphere |
| 10832 | Jay Park | Core Clinical Sciences | Assessing the Potential Effect of a New Diabetes Treatment in Canadian Populations | Lilly |
| 10835 | Surya Bhatt | RespirAnalytics LLC | Response to Long Acting Bronchodilators by STaging of Airflow Obstruction by the Ratio (STAR) versus Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages of Chronic Obstructive Pulmonary Disease | Boehringer Ingelheim |
| 10836 | Jean-Charles Nault | Université Paris Cité | Machine learning based prediction of Survival and Progression to atezolizumab-bevacizumab in Hepatocellular Carcinoma (HCC) patients | Roche |
| 10842 | Youqi Yang | Department of Biostatistics, University of Michigan | Estimating the Effect of Tirzepatide on Body Weight in Specific Subgroups: A Secondary Analysis Across Trials | Lilly |
| 10843 | Calvin Ke | University Health Network | Efficacy of Glucose-Lowering Drugs for Young-Onset Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomized Control Trials | GlaxoSmithKline |
| 10850 | Simon Cauchemez | Institut Pasteur | Evaluating the impact of Baloxavir on dynamics of influenza within-host infection and within-household transmission | Roche |
| 10852 | Ramona Belfiore-Oshan | Critical Path Institute | Development of an Artificial Intelligence/Machine Learning (AI/ML) model-based clinical trial simulation platform to better characterize Loss of Ambulation in Duchenne Muscular Dystrophy (DMD) | Cure Duchenne |
| 10855 | Stefan Leucht | Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, School of Medicine and Health, Technical University of Munich | Sex differences in the efficacy and tolerability of antidepressants in the acute treatment of people with major depressive disorder: an individual-participant-data, dose-response, network meta-analysis | Lundbeck, Lilly, GlaxoSmithKline, Pfizer Inc., Takeda |
| 10856 | Jennifer Lees | University of Glasgow | How Multimorbidity Affects Cancer Treatment: Analyzing the Impact on Treatment Safety and Effectiveness in Clinical Trials | AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, ONO, Pfizer Inc., Roche, Sanofi |
| 10866 | William Phillips | University of Ottawa | A longitudinal time-based assessment of toxicity prevalence and grade of targeted therapies and chemotherapy for treatment of advanced non-small cell lung cancer | AstraZeneca, Boehringer Ingelheim, Pfizer Inc. |
| 10870 | Sofia Ramiro | Leiden University Medical Center | Do fatty lesions explain why inflammation or erosions lead to new bone formation in axial spondyloarthritis (SpA)? | Lilly, Pfizer Inc., UCB |
| 10916 | Shane Goodwin | Western University | Predictability of biomarkers and disease activity indices for efficacy of advanced therapies in Crohn’s disease | Johnson & Johnson, Takeda, AbbVie |
| 10940 | Neeraj Narula | Hamilton Health Sciences | Comparison of Onset of Efficacy of Therapies for Ulcerative Colitis Based on Patient Symptom Diary Data version 2 | Johnson & Johnson, AbbVie, Takeda, Lilly, Pfizer Inc. |
| 10954 | tianpei Hong | Peking University Third Hospital | Sodium glucose cotransporter 2 (SGLT2) inhibitors improve islet function in patients with type 2 diabetes by reducing plasma ketone body levels | Boehringer Ingelheim |
| 10956 | William Harris | Fatty Acid Research Institute | Exploring the Link Between Blood Fatty Acids and Cardiovascular Health Outcomes in the STRENGTH Study | AstraZeneca |
| 10960 | Yin Bun Cheung | Duke-NUS Medical School, Centre for Quantitative Medicine | Extend previously approved access at CSDR (Research Proposal 12163): Novel approaches to the modelling of protective efficacy, immunity and infectious disease incidence: Malaria vaccination | GlaxoSmithKline |
| 10997 | Ricky Turgeon | University of British Columbia | Re-analyzing Heart Failure Treatment Outcomes Based on Patient Preferences: A Study Using Data from Multiple Clinical Trials | Boehringer Ingelheim |
| 10999 | David Cherney | University Health Network | Kidney Outcomes with Sodium-glucose co-transporter-2 Inhibitors (SGLT2i) in Patients with type 2 diabetes (T2D) and Atherosclerotic cardiovascular disease (ASCVD): Insights from the VERTIS-CV Study within the SMART-C Framework | Pfizer Inc. |
| 11001 | João Pedro Ferreira | Faculty of Medicine of Porto University | Sodium-glucose co-transporter 2 inhibitors induced polycythemia and risk of cardiovascular events | Boehringer Ingelheim, Johnson & Johnson |
| 11003 | Vitalay Fomin | Numenos | Placebo effect estimation utilizing large language model | Lilly |
| 11005 | Shane Goodwin | Western University | Disease and personal characteristics influencing the efficacy and safety of advanced therapies in moderate to severely active Crohn’s disease: Meta-analysis of individual patient data from randomized controlled trials | Johnson & Johnson, Takeda, AbbVie |
| 11010 | João Pedro Ferreira | Faculty of Medicine of Porto University | Serum magnesium and the effect of empagliflozin in heart failure | Boehringer Ingelheim |
| 11011 | Zahari Kassabov | Opificio Ltd | Study of diabetes metrics during exercise to understand how to improve glycemic control in patients | Jaeb Center for Health Research Foundation, Inc. |
| 11012 | Ali Ezzati | University of California, Irvine | Predictors of Treatment Response to Acute and Preventive Medications in Migraine: Insights from the OVERCOME Study | Lilly |
| 11018 | Iveta Jancigova | IQVIA | Optimizing dose-finding in early oncology trials by utilizing information from multiple measures and simulations | Daiichi Sankyo, Inc., Takeda |
| 11020 | Joshua Baker | University of Pennsylvania | Validation of Disease Activity Measurement Thresholds for Arthritis Treatment | Bristol Myers Squibb |
| 11021 | Ahmad Abuhelwa | University of Sharjah | Predictors of therapeutic and adverse effects outcomes of acalabrutinib used in the treatment of chronic lymphocytic leukemia | AstraZeneca |
| 11037 | Alexandre Betourne | Critical Path Institute | Integration of Biogen Amyotrophic Lateral Sclerosis Data into the Rare Diseases Cures Accelerator Data and Analytics Platform (RDCA-DAP) | Biogen |
| 11038 | Andrew Strahs | Wave Life Sciences | Analysis of PRO-DMD-01 Functional Data to Inform Endpoints in Wave’s FORWARD-53 Study of WVE-N531 for Duchenne Muscular Dystrophy (DMD) Exon-53 Skipping Therapy | Cure Duchenne |
| 11041 | Alessio Cortellini | Department of Surgery and CAncer, Imperial College London (UK) | Differential effect of systemic antibiotics and proton pump inhibitors on clinical outcomes from adjuvant immunotherapy or best supportive in patients with resected early stage NSCLC (stage III): A post-hoc analysis of the Impower010 trial. | Roche |
| 11058 | Shane Goodwin | Western University | Impact of disease and patient specific factors on the efficacy and safety of advanced therapies in moderate-to-severe Ulcerative colitis: An individual patient data meta-analysis of multiple clinical trials | Takeda, AbbVie, Johnson & Johnson, Lilly, Pfizer Inc. |
| 11065 | Felicitas Huber | Washington University in St. Louis | Examining the Impact of Stigma in Migraine On Treatment Seeking Behaviors, Migraine Concealment, And Psychological Well-Being | Lilly |
| 11067 | Samuel Maidman | Icahn School of Medicine at Mount Sinai | A pooled analysis of all Evinacumab studies assessing the effect of the drug on lipoprotein(a) levels | Regeneron |
| 11086 | Mingfang Li | The First Affiliated Hospital of Nanjing Medical University | Impact of Heart Failure Treatment and Empagliflozin on Stroke Risk in People with Atrial Fibrillation and Heart Failure: A Secondary Analysis from the EMPEROR-Preserved Study | Boehringer Ingelheim |
| 11088 | Neeraj Narula | Hamilton Health Sciences | Delayed Clinical Response to Adalimumab in Patients with Crohn’s Disease | AbbVie |
| 11090 | Alessio Cortellini | Department of Surgery and Cancer, Imperial College London (UK) | Opioid use and the efficacy of immune checkpoint blockade in patients with extensive-stage small-cell lung cancer: A post hoc analysis of CASPIAN trial | AstraZeneca |
| 11121 | James Galloway | Centre for Rheumatic Diseases, King's College London | The PARADOx (Progression Analysis in Rheumatoid Arthritis of raDiographic Outcomes) systematic review: Radiographic Progression and Treatment Tapering in Rheumatoid Arthritis | AbbVie, Pfizer Inc., UCB |
| 11130 | Joseph Doyle | MIT Sloan School of Management | Understanding the Impact of Diabetes Intervention Eligibility on Treatment Outcomes | Lilly |
| 11132 | Thomas Powles | Barts Cancer Institute | Health related-quality of life (HRQoL) and defining immune related adverse events (irAE) in patients with renal cell carcinoma (RCC) offered adjuvant immune checkpoint inhibitor (ICI) | Roche |
| 11138 | Greg Hapgood | Metro South Health | Assessing the Early Progression and Survival of Follicular Lymphoma Patients Compared to the General Population from the GALLIUM Trial | Roche |
| 11143 | Sujin Lee | Chung-ang University | The Impact of Antibiotic Use on the Efficacy of Immune Checkpoint Inhibitors in Cancer Treatment: A Meta-Analysis | Roche, Lilly |
| 11162 | Morgan Grams | NYU Grossman School of Medicine | Global Study on How Chronic Kidney Disease Affects Cardiovascular Disease Risk | Boehringer Ingelheim |
| 11194 | Cade Shadbolt | University of Melbourne | Tirzepatide versus placebo in adults with osteoarthritis and obesity: a secondary analysis of the SURMOUNT 1, 2, and 3 randomised trials | Lilly |
| 11196 | Jeong Il Yu | Department of radiation oncology, Samsung Medical Center | Evaluating the Effectiveness of Proton Beam Radiotherapy Combined with Atezolizumab and Bevacizumab for Primary Liver Cancer with Portal Vein Invasion: The PORTAL Study | Roche |
| 11201 | Sicong Ma | NYU Langone Health | Markers predicting immune-related adverse events of atezolizumab in lung cancer | Roche |
| 11246 | Paolo Napoletano | University of Milano-Bicocca | Personalized Blood Glucose Prediction Using Multimodal Real-Life Data and Artificial Intelligence | Jaeb Center for Health Research Foundation, Inc. |
| 11263 | Jacob Ollech | Rabin Medical Center | Identifying Factors That Predict Treatment Success in Patients with Chronic Pouchitis Using Vedolizumab | Takeda |
| 11275 | jahannaz dastgir | REGENXBIO Inc. Rockville, MD | Analysis of functional data from Duchenne participants in a natural history study and the placebo control arm of an interventional clinical trial for the treatment of Duchenne in combination with other natural history data sets. | Cure Duchenne |
| 11277 | María S Soengas | Fundación Sector Público Estatal Centro Nacional Investigaciones Oncológicas Carlos III (CNIO) | Improving Biomarker Identification for Melanoma Immunotherapy Using Ribonucleic Acid (RNA) Analysis | Bristol Myers Squibb |
| 11278 | Temiloluwa Prioleau | Emory University | Comparative analysis of publicly accessible diabetes datasets | Jaeb Center for Health Research Foundation, Inc. |
| 11281 | Carmen Castrillo | Avidity Biosciences | Analysis of progression on functional endpoints over time for participants in the PRO-DMD natural history database | Cure Duchenne |
| 11325 | Seong-Keun Yoo | Samsung Medical Center | Development of deep learning model predicting immune checkpoint inhibitor outcomes in urothelial bladder carcinoma | Roche |
| 11327 | Shenghong Zhang | The first affiliated hospital of Sun Yat-sen University | Predictors for therapeutic outcomes in patients with ulcerative colitis receiving Janus kinase inhibitor | Alfasigma |
| 11328 | Katie Bechman | King's College London | Effects of obesity on treatment response to Janus kinase inhibitors (JAKi) in rheumatoid arthritis | Alfasigma, Pfizer Inc., Lilly, AbbVie |
| 11350 | Neeraj Narula | Hamilton Health Sciences | Modified Multiplier Simple Endoscopic Score for Crohn's Disease (MM-SES-CD) Thresholds as Predictors of Delayed Clinical Response to Upadacitinib in Patients with Crohn’s Disease | AbbVie |
| 11369 | Neeraj Narula | Hamilton Health Sciences | Histologic Activity as a Prognostic Marker in Post-Induction Ulcerative Colitis: A Post-Hoc Analysis of the VARSITY Trial | Takeda |
| 11370 | Takaaki Maekawa | National Defense Medical College | Analysis of whether Plerixafor can be used as a single agent for rapid collection of blood stem cells in advance of potential radiation exposure | Sanofi |
| 11425 | Neeraj Narula | Hamilton Health Sciences | Serum and Histologic Eosinophilia as a Predictive Biomarker of Response to Mirkizumab in Ulcerative Colitis | Lilly |
| 11456 | Issa Dahabreh | Harvard T.H. Chan School of Public Health | Advancing methods for applying the results of clinical trials to data from medical insurance claims for patients taking anti-coagulants for non-valvular atrial fibrillation | Boehringer Ingelheim, Daiichi Sankyo, Inc. |
| 11465 | Ullrich O. Wenzel | University Medical Center Hamburg-Eppendorf | Tirzepatide and Systolic Blood Pressure: An Individual Patient Metaanalysis | Lilly |
| 11487 | Gonzalo Spera | Translational Research in Oncology | The Association between Beta-blockers and Outcomes in Triple Negative Breast Cancer | Roche |
| 11561 | JOAN BUSNER | Signant Health | Psychometric analysis of the Children's Depression Rating Scale-Revised (CDRS-R) in a large international study of pediatric Major Depressive Disorder (MDD) | Lundbeck |
| 11690 | Soumyajit Roy | University Hospitals Cleveland Medical Center | Training and Validation of PSA and Pain as Biomarkers and Causal Mediators in Metastatic Hormone Sensitive Prostate Cancer | Bayer, Johnson & Johnson, Astellas |
| 11694 | Jun Mao | Memorial Sloan Kettering Cancer Center | TransPALLAS (NCT02513394) | Alliance Foundation Trials, LLC (AFT) |
| 11705 | Paolo Ranzi | Gruppo Per l'Informatica (GPI) S.p.A. | Prediction of glucose dynamics by Bayesian modeling | Jaeb Center for Health Research Foundation, Inc. |
